Use of riluzole

MNMED_RILUZOLE

No definition available.

Endpoint definition

↥

Report an error or suggest an improvement for this endpoint codes

Endpoint definition steps	FinnGen
Phenotype data	519870
1. Apply sex-specific rule None	519870
2. Check conditions None	519870
3. Check pre-conditions, main-only, mode, registry filters Registry filters: Medicine purchases: ATC — N07XX02 1 out of 7 registries used, show all original rules.	151
4. Check minimum number of events Min. number of events 3	151
5. Include endpoints None	151
6. Filter based on genotype QC (FinnGen only)	145

Control definitions (FinnGen only)

Controls for this endpoint are individuals that are not cases.

Extra metadata

First used in FinnGen datafreeze: DF2

NAME	MNMED_RILUZOLE
CONTROL_EXCLUDE
CONTROL_PRECONDITIONS
CONTROL_CONDITIONS
SEX
INCLUDE
PRE_CONDITIONS
CONDITIONS
OUTPAT_ICD
OUTPAT_OPER
HD_MAINONLY
HD_ICD_10_ATC
HD_ICD_10
HD_ICD_9
HD_ICD_8
HD_ICD_10_EXCL
HD_ICD_9_EXCL
HD_ICD_8_EXCL
COD_MAINONLY
COD_ICD_10
COD_ICD_9
COD_ICD_8
COD_ICD_10_EXCL
COD_ICD_9_EXCL
COD_ICD_8_EXCL
OPER_NOM
OPER_HL
OPER_HP1
OPER_HP2
KELA_REIMB
KELA_REIMB_ICD
KELA_ATC_NEEDOTHER
KELA_ATC	N07XX02
KELA_VNRO_NEEDOTHER
KELA_VNRO
CANC_TOPO
CANC_TOPO_EXCL
CANC_MORPH
CANC_MORPH_EXCL
CANC_BEHAV

Similar endpoints

↥

List of similar endpoints to Use of riluzole based on the number of shared cases.

Similar with more cases:

Similar with less cases:

None

Case counts by codes

↥

FinnGen case counts by registry codes:

Not enough data for upset plot.

Full data table

Summary Statistics

↥

-FinRegistry-

This endpoint is excluded from FinRegistry analyses (omitted endpoint).

-FinnGen-

Key figures

	All	Female	Male
Number of individuals	145	64	81
Unadjusted period prevalence (%)	0.03	0.02	0.04
Median age at first event (years)	65.62	66.37	65.03

-FinnGen-

Age distribution of first events

-FinnGen-

Year distribution of first events

-FinnGen-

Cumulative Incidence Function

Not a core endpoint, no data to show.

CodeWAS

↥

CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.

This is a new tool, please reach out using the contact form for feedback and improvement ideas.

First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log₁₀(p-value) ≥ 6.

Matched cohort

Matched cases
151: Matched controls
1510

Code

Vocabulary

Description

Odds Ratio

-log₁₀(p)

N matched cases

N matched controls

N07XX02

ATC

riluzole; oral

+∞

218.3

151

G12.2

ICD-10 Finland

Motor neuron disease

6269.6

192.5

144

504

Kela drug reimbursment

Conditions requiring daily forced enteral nutrition

108.7

126.2

J96.1

ICD-10 Finland

Chronic respiratory failure

61.2

93.8

Z51.5

ICD-10 Finland

Palliative care

14.7

60.3

N99

ICPC

Neurological disease other

163.8

60.1

R4130

NOMESCO Finland

Speech therapy

22.5

48.8

JDB10

NOMESCO Finland

Percutaneous gastrostomy

105.5

47.5

R47.1

ICD-10 Finland

Dysarthria and anarthria

69.3

33.1

R29.8

ICD-10 Finland

Other and unspecified symptoms and signs involving the nervous and musculoskeletal systems

9.4

31.6

R13

ICD-10 Finland

Dysphagia

9.1

30.3

N28

ICPC

Limited function/disability (N)

64.4

27.4

WX725

NOMESCO Finland

Noninvasive ventilation

8.6

21.7

R4120

NOMESCO Finland

Occupational therapy

7.5

19.8

R4190

NOMESCO Finland

Nutritional therapy

20.8

19.7

R5110

NOMESCO Finland

Evaluation of the need for aids, the testing, fitting and choice of the aid, instruction in use and delivery of it

5.3

18.9

121

NA1BG

NOMESCO Finland

Cervical spine MRI examination with high intensity magnet

8.4

17.5

TJD20

NOMESCO Finland

Change of gastrostomy tube

101.5

17.0

A28

ICPC

Limited function/disability NOS

4.3

16.7

204

G12.9

ICD-10 Finland

Spinal muscular atrophy, unspecified

+∞

15.9

TAB00

NOMESCO Finland

Lumbar puncture

6.8

13.0

N02AA01

ATC

morphine; systemic, rectal

18.4

12.0

R1250

NOMESCO Finland

Evaluation of functional capability

13.4

11.7

R5599

NOMESCO Finland

Other rehabilitation service

11.9

11.2

XG466

NOMESCO Finland

Sleep oxymetry

10.0

10.7

L28

ICPC

Limited function/disability (L)

3.3

10.0

191

Z71.3

ICD-10 Finland

Dietary counselling and surveillance

8.7

9.5

G62.9

ICD-10 Finland

Polyneuropathy, unspecified

9.3

9.4

SPAT1229

SPAT

Assessment of need for aid

4.6

9.2

AA1BG

NOMESCO Finland

Standard MRI examination of brain with high intensity magnet

4.0

9.2

R1260

NOMESCO Finland

Evaluation of communicative skills

15.3

8.9

R5140

NOMESCO Finland

Monitoring the use of the aid

3.4

8.2

118

GX2D5

NOMESCO Finland

Sleep oximetry

84.0

7.5

N03AE01

ATC

clonazepam; systemic

4.9

7.4

R5110, ,

SPAT

3.8

7.2

I50.9

ICD-10 Finland

Heart failure, unspecified

0.0

6.6

186

FM1EE

NOMESCO Finland

Extensive structural and functional ultrasound examination of heart

0.2

6.4

299

R47.8

ICD-10 Finland

Other and unspecified speech disturbances

13.3

6.2

J69.0

ICD-10 Finland

Pneumonitis due to food and vomit

10.7

6.1

Z46.8

ICD-10 Finland

Fitting and adjustment of other specified devices

6.9

6.0

TimeCodeWAS

↥

TODO / Current known limitations:

Only showing the top 300 codes, because showing all (sometimes 20k) makes the page too slow.
Legend / how to read the glyphs.
Show details (e.g. Fisher or Chi-square test, LR+, etc.) when clicking on a row.
Explanation on the underlying data / how the TimeCodeWAS is done (e.g. matched cases / controls, eligibility).
Download CSV.
No filters and sorters.
Limited amount of endpoints (~400) having TimeCodeWAS data.
Cross-links to Risteys lab test pages for lab test codes.

OMOP concept

ln(OR)

%cases with code / %controls with code

2×2 table

Pharmacy visit
OMOP4822462 [581458]

-4.4e-01

1.5e-01

1.8e-01

1.0e+50

1.1e+00

1.0e+50

—

cases:93.38%

controls:95.63%

cases:90.73%

controls:89.40%

cases:57.62%

controls:53.25%

cases:100.00%

controls:1.72%

cases:78.15%

controls:54.83%

cases:100.00%

controls:87.55%

—

141

1444

137

1350

160

804

706

151

1484

118

828

682

132

1301

185

—

Neurology
13 [38004458]

9.2e-01

4.1e+00

5.5e+00

—

4.8e+00

5.8e+00

—

cases:25.83%

controls:12.19%

cases:77.48%

controls:5.17%

cases:76.82%

controls:1.39%

—

cases:49.01%

controls:0.79%

cases:95.45%

controls:6.06%

—

184

112

1326

117

1432

116

1489

—

1498

126

1396

—

Pulmonary Disease
29 [38004472]

2.2e-01

1.2e+00

2.3e+00

—

2.9e+00

3.3e+00

—

cases:15.23%

controls:12.58%

cases:19.21%

controls:6.82%

cases:11.92%

controls:1.39%

—

cases:15.23%

controls:0.99%

cases:62.88%

controls:5.92%

—

190

128

1320

103

122

1407

133

1489

—

128

1495

1398

—

Outpatient Visit
OP [9202]

1.8e-01

1.2e+00

1.6e+00

2.8e+00

1.6e+00

2.4e+00

—

cases:78.81%

controls:75.63%

cases:81.46%

controls:55.89%

cases:37.75%

controls:11.06%

cases:9.93%

controls:0.66%

cases:35.76%

controls:10.40%

cases:93.18%

controls:56.33%

—

119

1142

368

123

844

666

167

1343

136

1500

157

1353

123

837

649

—

Physical Medicine And Rehabilitation
25 [38004468]

7.0e-01

2.5e+00

3.2e+00

—

3.3e+00

—

cases:11.92%

controls:6.29%

cases:19.21%

controls:1.85%

cases:9.93%

controls:0.46%

—

cases:34.85%

controls:1.95%

—

133

1415

122

1482

136

1503

—

1457

—

Polyneuropathy, unspecified
G62.9 [45566898]

2.5e+00

3.4e+00

—

1.0e+50

2.5e+00

—

cases:3.97%

controls:0.33%

cases:9.27%

controls:0.33%

—

cases:3.97%

controls:0.00%

cases:3.79%

controls:0.34%

—

145

1505

137

1505

—

145

1510

127

1481

—

Inpatient Hospital
21 [8717]

2.4e-02

1.1e+00

3.2e+00

—

1.8e+00

1.7e+00

—

cases:33.11%

controls:32.58%

cases:25.17%

controls:10.13%

cases:18.54%

controls:0.93%

—

cases:8.61%

controls:1.52%

cases:34.09%

controls:8.41%

—

492

101

1018

153

113

1357

123

1496

—

138

1487

125

1361

—

Dysphagia
R13 [45573013]

—

3.6e+00

—

4.0e+00

—

cases:10.60%

controls:0.33%

—

cases:15.15%

controls:0.34%

—

135

1505

—

112

1481

—

Office Visit
OMOP4822458 [581477]

-1.7e-01

1.7e+00

—

3.0e+00

2.6e+00

—

cases:8.61%

controls:10.07%

cases:9.93%

controls:2.05%

—

cases:7.28%

controls:0.40%

cases:18.94%

controls:1.75%

—

152

138

1358

136

1479

—

140

1504

107

1460

—

Inpatient Visit
IP [9201]

1.4e-01

8.1e-01

2.2e+00

—

2.4e+00

—

cases:7.95%

controls:6.95%

cases:8.61%

controls:4.04%

cases:4.64%

controls:0.53%

—

cases:6.62%

controls:0.66%

cases:30.30%

controls:3.77%

—

105

139

1405

138

1449

144

1502

—

141

1500

1430

—

Home Visit
OMOP4822459 [581476]

3.4e-01

1.5e+00

1.4e+00

—

2.3e+00

3.2e+00

—

cases:5.96%

controls:4.30%

cases:13.25%

controls:3.31%

cases:5.30%

controls:1.39%

—

cases:12.58%

controls:1.46%

cases:46.97%

controls:3.57%

—

142

1445

131

1460

143

1489

—

132

1488

1433

—

Physiotherapy
R4110 [2001310233]

7.8e-01

1.5e+00

2.3e+00

—

2.7e+00

—

cases:10.60%

controls:5.17%

cases:8.61%

controls:2.05%

cases:3.97%

controls:0.40%

—

cases:14.39%

controls:1.14%

—

135

1432

138

1479

145

1504

—

113

1469

—

Cell count panel - Cerebral spinal fluid
34563-7 [3044290]

2.5e+00

3.3e+00

—

cases:3.97%

controls:0.33%

cases:7.95%

controls:0.33%

—

145

1505

139

1505

—

Bilirubin.total [Moles/volume] in Serum or Plasma
14631-6 [3006140]

-1.4e-01

7.3e-01

1.9e+00

—

2.3e+00

1.6e+00

—

cases:12.58%

controls:14.17%

cases:16.56%

controls:8.74%

cases:12.58%

controls:2.19%

—

cases:13.91%

controls:1.66%

cases:32.58%

controls:8.82%

—

214

132

1296

132

126

1378

132

1477

—

130

1485

131

1355

—

Borrelia burgdorferi IgG Ab [Units/volume] in Serum
7817-0 [3016888]

1.9e+00

3.7e+00

—

cases:8.61%

controls:1.39%

cases:16.56%

controls:0.46%

—

138

1489

126

1503

—

Borrelia burgdorferi IgM Ab [Units/volume] in Serum
7818-8 [3008230]

1.8e+00

3.8e+00

1.0e+50

—

cases:9.27%

controls:1.59%

cases:17.22%

controls:0.46%

cases:3.31%

controls:0.00%

—

137

1486

125

1503

146

1510

—

Base excess.100% oxygenated [Moles/volume] standard in Capillary blood by calculation
72720-6 [43055554]

—

2.3e+00

—

3.2e+00

—

cases:5.30%

controls:0.53%

—

cases:9.09%

controls:0.40%

—

143

1502

—

120

1480

—

Glucose [Moles/volume] in Cerebral spinal fluid
14744-7 [3020044]

2.0e+00

3.5e+00

—

cases:3.97%

controls:0.53%

cases:9.93%

controls:0.33%

—

145

1502

136

1505

—

pH of Capillary blood
2745-8 [3009343]

—

2.3e+00

—

3.2e+00

—

cases:5.30%

controls:0.53%

—

cases:12.88%

controls:0.61%

—

143

1502

—

115

1477

—

Protein [Mass/volume] in Cerebral spinal fluid
2880-3 [3019473]

2.0e+00

3.4e+00

—

cases:3.97%

controls:0.53%

cases:9.27%

controls:0.33%

—

145

1502

137

1505

—

Carbon dioxide [Partial pressure] in Capillary blood
2020-6 [3023024]

—

2.2e+00

—

3.2e+00

—

cases:5.30%

controls:0.60%

—

cases:12.88%

controls:0.61%

—

143

1501

—

115

1477

—

Limited function/disability (L)
L28 [2002000647]

6.9e-01

2.2e+00

—

1.0e+50

3.2e+00

—

cases:5.30%

controls:2.72%

cases:8.61%

controls:1.06%

—

cases:5.30%

controls:0.00%

cases:18.18%

controls:0.87%

—

143

1469

138

1494

—

143

1510

108

1473

—

Other and unspecified symptoms and signs involving the nervous and musculoskeletal systems
R29.8 [45587505]

2.4e+00

—

2.7e+00

—

cases:9.27%

controls:0.93%

—

cases:6.82%

controls:0.47%

—

137

1496

—

123

1479

—

Limited function/disability NOS
A28 [2002000162]

8.9e-01

2.0e+00

1.7e+00

—

1.7e+00

3.0e+00

—

cases:3.31%

controls:1.39%

cases:6.62%

controls:0.99%

cases:3.31%

controls:0.60%

—

cases:3.31%

controls:0.60%

cases:21.97%

controls:1.35%

—

146

1489

141

1495

146

1501

—

146

1501

103

1466

—

Implementation of physical therapy rehabilitation plan
SPAT1223 [2001700324]

4.0e-01

2.0e+00

—

2.7e+00

—

cases:9.93%

controls:6.89%

cases:11.92%

controls:1.72%

—

cases:21.97%

controls:1.82%

—

104

136

1406

133

1484

—

103

1459

—

Functional capacity evaluation
443351003 [40481051]

6.6e-01

1.7e+00

—

3.0e+00

—

cases:4.64%

controls:2.45%

cases:5.30%

controls:1.06%

—

cases:16.67%

controls:0.94%

—

144

1473

143

1494

—

110

1472

—

Laboratory Visit
OMOP4822461 [32036]

-2.4e-02

2.8e-01

1.2e+00

2.3e+00

1.0e+00

5.4e-01

—

cases:53.64%

controls:54.24%

cases:58.28%

controls:51.32%

cases:41.06%

controls:16.75%

cases:5.30%

controls:0.53%

cases:35.76%

controls:16.56%

cases:63.64%

controls:50.54%

—

819

691

775

735

253

1257

143

1502

250

1260

751

735

—

Monocytes [#/volume] in Blood
26484-6 [3001604]

3.5e-01

7.0e-01

1.7e+00

—

1.6e+00

1.3e+00

—

cases:17.88%

controls:13.31%

cases:17.22%

controls:9.34%

cases:8.61%

controls:1.72%

—

cases:6.62%

controls:1.46%

cases:26.52%

controls:8.95%

—

201

124

1309

141

125

1369

138

1484

—

141

1488

133

1353

—

Basophils [#/volume] in Blood
26444-0 [3006315]

3.6e-01

7.0e-01

1.7e+00

—

1.6e+00

1.3e+00

—

cases:17.88%

controls:13.25%

cases:17.22%

controls:9.40%

cases:8.61%

controls:1.72%

—

cases:6.62%

controls:1.46%

cases:26.52%

controls:9.08%

—

200

124

1310

142

125

1368

138

1484

—

141

1488

135

1351

—

Protein electrophoresis panel - Serum or Plasma
24351-9 [3004588]

1.5e+00

2.9e+00

—

cases:6.62%

controls:1.59%

cases:13.25%

controls:0.79%

—

141

1486

131

1498

—

Eosinophils [#/volume] in Blood
26449-9 [3013115]

2.9e-01

6.5e-01

1.6e+00

—

1.5e+00

1.3e+00

—

cases:17.88%

controls:13.97%

cases:17.22%

controls:9.80%

cases:8.61%

controls:1.79%

—

cases:6.62%

controls:1.59%

cases:26.52%

controls:9.35%

—

211

124

1299

148

125

1362

138

1483

—

141

1486

139

1347

—

Lymphocytes [#/volume] in Blood
26474-7 [3019198]

2.9e-01

6.7e-01

1.6e+00

—

1.5e+00

1.2e+00

—

cases:17.88%

controls:14.04%

cases:17.22%

controls:9.60%

cases:8.61%

controls:1.79%

—

cases:6.62%

controls:1.59%

cases:26.52%

controls:9.49%

—

212

124

1298

145

125

1365

138

1483

—

141

1486

141

1345

—

Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma
1742-6 [3006923]

6.4e-02

5.0e-01

1.5e+00

—

1.8e+00

9.2e-01

—

cases:45.70%

controls:44.11%

cases:46.36%

controls:34.37%

cases:27.15%

controls:7.35%

—

cases:28.48%

controls:6.16%

cases:56.82%

controls:34.32%

—

666

844

519

991

111

110

1399

—

108

1417

510

976

—

amitriptyline; oral, parenteral
N06AA09 [21604696]

—

6.1e-01

—

2.3e+00

1.8e+00

—

cases:4.64%

controls:2.58%

—

cases:3.97%

controls:0.40%

cases:17.42%

controls:3.23%

—

144

1471

—

145

1504

109

1438

—

Outpatient Hospital
22 [8756]

3.0e-02

9.8e-01

1.9e+00

—

1.3e+00

—

cases:27.81%

controls:27.22%

cases:15.89%

controls:6.62%

cases:4.64%

controls:0.73%

—

cases:17.42%

controls:5.38%

—

411

109

1099

100

127

1410

144

1499

—

109

1406

—

Protein [Mass/volume] in Serum or Plasma
2885-2 [3020630]

1.5e+00

2.7e+00

—

cases:7.28%

controls:1.72%

cases:12.58%

controls:0.99%

—

140

1484

132

1495

—

Medical Oncology
90 [38004507]

—

6.7e-01

—

1.7e+00

2.4e+00

—

cases:6.62%

controls:3.51%

—

cases:7.95%

controls:1.52%

cases:27.27%

controls:3.36%

—

141

1457

—

139

1487

1436

—

IgG [Mass/volume] in Serum or Plasma
2465-3 [3005719]

1.5e+00

2.5e+00

—

cases:7.28%

controls:1.66%

cases:7.95%

controls:0.73%

—

140

1485

139

1499

—

Aid fitting and borrowing and monitoring of use
SPAT1230 [2001700331]

—

1.6e+00

—

2.4e+00

—

cases:5.96%

controls:1.32%

—

cases:9.85%

controls:0.94%

—

142

1490

—

119

1472

—

Palliative care
Z51.5 [45547323]

—

3.9e+00

—

cases:22.73%

controls:0.61%

—

102

1477

—

Audiology
64 [38004489]

3.3e-01

1.5e+00

—

2.2e+00

—

cases:4.64%

controls:3.38%

cases:7.28%

controls:1.72%

—

cases:13.64%

controls:1.68%

—

144

1459

140

1484

—

114

1461

—

Standard MRI examination of brain with high intensity magnet
AA1BG [2001300112]

1.2e+00

3.7e+00

—

cases:3.31%

controls:1.06%

cases:11.92%

controls:0.33%

—

146

1494

133

1505

—

Neutrophils/Leukocytes in Blood
26511-6 [3018010]

3.8e-01

8.3e-01

1.6e+00

—

9.4e-01

1.2e+00

—

cases:17.22%

controls:12.45%

cases:17.22%

controls:8.28%

cases:7.95%

controls:1.79%

—

cases:3.97%

controls:1.59%

cases:23.48%

controls:8.28%

—

188

125

1322

125

1385

139

1483

—

145

1486

123

101

1363

—

Monocytes/Leukocytes in Blood
26485-3 [3019069]

3.4e-01

8.6e-01

1.5e+00

—

9.8e-01

1.2e+00

—

cases:17.22%

controls:12.85%

cases:17.22%

controls:8.08%

cases:7.28%

controls:1.66%

—

cases:3.97%

controls:1.52%

cases:22.73%

controls:8.14%

—

194

125

1316

122

125

1388

140

1485

—

145

1487

121

102

1365

—

Eosinophils/Leukocytes in Blood
26450-7 [3006504]

3.7e-01

8.1e-01

1.5e+00

—

9.8e-01

1.2e+00

—

cases:17.22%

controls:12.52%

cases:16.56%

controls:8.08%

cases:7.28%

controls:1.66%

—

cases:3.97%

controls:1.52%

cases:22.73%

controls:8.01%

—

189

125

1321

122

126

1388

140

1485

—

145

1487

119

102

1367

—

Gas panel - Arterial blood
24336-0 [3019060]

—

3.5e+00

—

cases:12.12%

controls:0.40%

—

116

1480

—

Case Management Agency
251B00000X [38004193]

-2.2e-01

2.9e-03

1.1e+00

1.6e+00

8.3e-01

5.5e-01

—

cases:65.56%

controls:70.33%

cases:64.24%

controls:64.17%

cases:50.33%

controls:25.96%

cases:8.61%

controls:1.85%

cases:48.34%

controls:29.07%

cases:76.52%

controls:65.34%

—

1062

448

969

541

392

1118

138

1482

439

1071

101

971

515

—

Lymphocytes/Leukocytes in Blood
26478-8 [3002030]

3.6e-01

8.3e-01

1.5e+00

—

9.0e-01

1.1e+00

—

cases:17.88%

controls:13.18%

cases:17.22%

controls:8.34%

cases:7.28%

controls:1.72%

—

cases:3.97%

controls:1.66%

cases:22.73%

controls:8.61%

—

199

124

1311

126

125

1384

140

1484

—

145

1485

128

102

1358

—

MCHC [Entitic Mass/volume] in Red Blood Cells
28540-3 [3003338]

1.4e-01

4.8e-01

1.3e+00

—

1.4e+00

7.5e-01

—

cases:37.75%

controls:34.44%

cases:36.42%

controls:26.16%

cases:19.87%

controls:6.56%

—

cases:19.87%

controls:5.83%

cases:42.42%

controls:25.91%

—

520

990

395

1115

121

1411

—

121

1422

385

1101

—

MCH [Entitic mass]
28539-5 [3035941]

-5.3e-03

4.5e-01

1.3e+00

—

1.2e+00

8.0e-01

—

cases:49.67%

controls:49.80%

cases:52.32%

controls:41.19%

cases:29.14%

controls:10.00%

—

cases:27.15%

controls:9.80%

cases:61.36%

controls:41.59%

—

752

758

622

888

151

107

1359

—

148

110

1362

618

868

—

MCV [Entitic mean volume] in Red Blood Cells
30428-7 [3024731]

-5.3e-03

4.5e-01

1.3e+00

—

1.2e+00

8.0e-01

—

cases:49.67%

controls:49.80%

cases:52.32%

controls:41.19%

cases:29.14%

controls:10.00%

—

cases:27.15%

controls:9.80%

cases:61.36%

controls:41.66%

—

752

758

622

888

151

107

1359

—

148

110

1362

619

867

—

Hematocrit [Volume Fraction] of Blood by calculation
20570-8 [3009542]

-7.9e-03

4.8e-01

1.3e+00

—

1.2e+00

8.0e-01

—

cases:49.67%

controls:49.87%

cases:52.98%

controls:41.19%

cases:29.14%

controls:10.00%

—

cases:27.15%

controls:9.80%

cases:61.36%

controls:41.66%

—

753

757

622

888

151

107

1359

—

148

110

1362

619

867

—

Leukocytes [#/volume] in Blood
26464-8 [3010813]

-5.3e-03

4.5e-01

1.3e+00

—

1.2e+00

8.0e-01

—

cases:49.67%

controls:49.80%

cases:52.32%

controls:41.19%

cases:29.14%

controls:10.00%

—

cases:27.15%

controls:9.80%

cases:61.36%

controls:41.66%

—

752

758

622

888

151

107

1359

—

148

110

1362

619

867

—

Erythrocytes [#/volume] in Blood
26453-1 [3026361]

-5.3e-03

4.5e-01

1.3e+00

—

1.2e+00

8.0e-01

—

cases:49.67%

controls:49.80%

cases:52.32%

controls:41.19%

cases:29.14%

controls:10.00%

—

cases:27.15%

controls:9.80%

cases:61.36%

controls:41.66%

—

752

758

622

888

151

107

1359

—

148

110

1362

619

867

—

Hemoglobin [Mass/volume] in Blood
718-7 [3000963]

-5.3e-03

4.5e-01

1.3e+00

—

1.2e+00

8.0e-01

—

cases:49.67%

controls:49.80%

cases:52.32%

controls:41.19%

cases:29.14%

controls:10.00%

—

cases:27.15%

controls:9.80%

cases:61.36%

controls:41.66%

—

752

758

622

888

151

107

1359

—

148

110

1362

619

867

—

Platelets [#/volume] in Blood
26515-7 [3007461]

2.6e-03

4.3e-01

1.3e+00

—

1.2e+00

8.0e-01

—

cases:49.67%

controls:49.60%

cases:51.66%

controls:41.13%

cases:29.14%

controls:10.00%

—

cases:27.15%

controls:9.80%

cases:61.36%

controls:41.72%

—

749

761

621

889

151

107

1359

—

148

110

1362

620

866

—

Bicarbonate [Moles/volume] in Capillary blood
1961-2 [3015235]

-1.0e+50

—

3.3e+00

—

cases:0.00%

controls:0.53%

—

cases:9.85%

controls:0.40%

—

151

1502

—

119

1480

—

Evaluation of the need for aids, the testing, fitting and choice of the aid, instruction in use and delivery of it
R5110 [2001310246]

—

3.3e+00

—

cases:15.15%

controls:0.67%

—

112

1476

—

Protein.monoclonal band 1 [Mass/volume] in Serum or Plasma by Electrophoresis
51435-6 [3029713]

—

3.3e+00

—

cases:7.95%

controls:0.33%

—

139

1505

—

Holo-transcobalamin II [Moles/volume] in Serum
72160-5 [43054903]

4.8e-01

1.0e+00

2.2e+00

—

1.1e-01

—

cases:14.57%

controls:9.54%

cases:11.92%

controls:4.64%

cases:4.64%

controls:0.53%

—

cases:6.06%

controls:5.45%

—

144

129

1366

133

1440

144

1502

—

124

1405

—

Supplier / Service Provider
OMOP5117446 [33004]

-3.4e-01

3.0e-01

1.0e+00

—

3.2e+00

—

cases:21.19%

controls:27.48%

cases:11.26%

controls:8.61%

cases:3.97%

controls:1.46%

—

cases:12.88%

controls:0.61%

—

415

119

1095

130

134

1380

145

1488

—

115

1477

—

Protein.monoclonal band 3 [Mass/volume] in Serum or Plasma by Electrophoresis
50796-2 [3029338]

—

3.2e+00

—

cases:7.28%

controls:0.33%

—

140

1505

—

Protein.monoclonal band 4 [Mass/volume] in Serum or Plasma by Electrophoresis
50797-0 [3029379]

—

3.2e+00

—

cases:7.28%

controls:0.33%

—

140

1505

—

Protein.monoclonal band 2 [Mass/volume] in Serum or Plasma by Electrophoresis
35559-4 [3035797]

—

3.2e+00

—

cases:7.28%

controls:0.33%

—

140

1505

—

Erythrocyte [DistWidth] in Red Blood Cells
30385-9 [3002385]

6.4e-02

3.1e-01

1.2e+00

—

1.1e+00

7.8e-01

—

cases:32.45%

controls:31.06%

cases:31.13%

controls:24.83%

cases:17.88%

controls:6.16%

—

cases:17.22%

controls:6.29%

cases:44.70%

controls:26.99%

—

469

102

1041

375

104

1135

124

1417

—

125

1415

401

1085

—

Gas panel - Central venous blood
97535-9 [1616796]

-1.0e+50

—

3.1e+00

—

cases:0.00%

controls:0.53%

—

cases:6.82%

controls:0.34%

—

151

1502

—

123

1481

—

Alpha 1 globulin [Mass/volume] in Serum or Plasma by Electrophoresis
2865-4 [3015322]

1.5e+00

3.0e+00

—

cases:3.97%

controls:0.93%

cases:8.61%

controls:0.46%

—

145

1496

138

1503

—

Calcium.ionized [Moles/volume] adjusted to pH 7.4 in Serum or Plasma
19072-8 [3016431]

3.5e-01

1.0e+00

1.8e+00

—

4.8e-01

—

cases:17.88%

controls:13.31%

cases:17.88%

controls:7.35%

cases:4.64%

controls:0.79%

—

cases:12.12%

controls:7.87%

—

201

124

1309

111

124

1399

144

1498

—

117

116

1369

—

Gamma globulin [Mass/volume] in Serum or Plasma by Electrophoresis
2874-6 [3023465]

1.6e+00

2.8e+00

—

cases:3.97%

controls:0.86%

cases:7.95%

controls:0.53%

—

145

1497

139

1502

—

Body temperature
8310-5 [3020891]

-1.0e+50

—

2.8e+00

—

cases:0.00%

controls:0.66%

—

cases:9.85%

controls:0.67%

—

151

1500

—

119

1476

—

Alpha 2 globulin [Mass/volume] in Serum or Plasma by Electrophoresis
2868-8 [3005229]

1.5e+00

2.8e+00

—

cases:3.97%

controls:0.93%

cases:8.61%

controls:0.60%

—

145

1496

138

1501

—

Beta 1 globulin [Mass/volume] in Serum or Plasma by Electrophoresis
32730-4 [3043723]

1.5e+00

2.8e+00

—

cases:3.97%

controls:0.93%

cases:8.61%

controls:0.60%

—

145

1496

138

1501

—

Beta 2 globulin [Mass/volume] in Serum or Plasma by Electrophoresis
32731-2 [3043747]

1.5e+00

2.8e+00

—

cases:3.97%

controls:0.93%

cases:8.61%

controls:0.60%

—

145

1496

138

1501

—

Basophils/Leukocytes in Blood
30180-4 [3022096]

3.9e-01

8.0e-01

1.5e+00

—

9.8e-01

1.2e+00

—

cases:17.22%

controls:12.38%

cases:16.56%

controls:8.21%

cases:7.28%

controls:1.66%

—

cases:3.97%

controls:1.52%

cases:22.73%

controls:8.08%

—

187

125

1323

124

126

1386

140

1485

—

145

1487

120

102

1366

—

Assessment of need for aid
SPAT1229 [2001700330]

—

2.7e+00

—

cases:6.82%

controls:0.47%

—

123

1479

—

Teaching
WZC30 [2001310891]

—

1.3e+00

—

2.7e+00

—

cases:3.31%

controls:0.93%

—

cases:10.61%

controls:0.81%

—

146

1496

—

118

1474

—

Support of social functional capacity
SPAT1234 [2001700335]

-1.0e+50

—

2.6e+00

—

cases:0.00%

controls:0.66%

—

cases:4.55%

controls:0.34%

—

151

1500

—

126

1481

—

Assessment of need for services (elderly/care support)
SPAT1217 [2001700318]

-1.0e+50

—

2.6e+00

—

cases:0.00%

controls:0.79%

—

cases:5.30%

controls:0.40%

—

151

1498

—

125

1480

—

Voluntary or Charitable Agency
251V00000X [38004202]

-1.0e+50

—

2.6e+00

—

cases:0.00%

controls:0.33%

—

cases:5.30%

controls:0.40%

—

151

1505

—

125

1480

—

Nuclear Ab [Titer] in Serum
29953-7 [3037522]

7.5e-01

2.5e+00

—

cases:5.96%

controls:2.91%

cases:9.27%

controls:0.79%

—

142

1466

137

1498

—

Lumbar puncture
TAB00 [2001300538]

2.5e+00

—

cases:3.97%

controls:0.33%

—

145

1505

—

pH of Blood
11558-4 [3010421]

-1.0e+50

—

2.5e+00

—

cases:0.00%

controls:0.93%

—

cases:4.55%

controls:0.40%

—

151

1496

—

126

1480

—

Counselling and guidance related to physical exercise
SPAT1305 [2001700406]

-1.0e+50

—

2.5e+00

—

cases:0.00%

controls:1.92%

cases:0.00%

controls:0.33%

—

cases:3.79%

controls:0.34%

—

151

1481

151

1505

—

127

1481

—

Creatine kinase [Enzymatic activity/volume] in Serum or Plasma
2157-6 [3007220]

6.2e-01

2.4e+00

—

2.7e-01

—

cases:13.91%

controls:8.01%

cases:29.14%

controls:3.51%

—

cases:4.55%

controls:3.50%

—

121

130

1389

107

1457

—

126

1434

—

Esophagoscopy, gastroscopy and duodenoscopy
UJD10 [2001304788]

-3.0e-02

7.1e-01

—

2.4e+00

—

cases:4.64%

controls:4.77%

cases:3.97%

controls:1.99%

—

cases:12.88%

controls:1.35%

—

144

1438

145

1480

—

115

1466

—

Nursing episode
950 [44777714]

—

2.3e+00

—

cases:9.09%

controls:0.94%

—

120

1472

—

Counselling/guidance promoting independent living
SPAT1222 [2001700323]

—

2.3e+00

—

cases:8.33%

controls:0.87%

—

121

1473

—

Base excess in Arterial blood by calculation
1925-7 [3003396]

6.5e-01

—

1.0e+50

—

2.3e+00

—

cases:3.97%

controls:2.12%

—

cases:3.31%

controls:0.00%

—

cases:10.61%

controls:1.14%

—

145

1478

—

146

1510

—

118

1469

—

Internal Medicine
11 [38004456]

1.8e-01

8.7e-01

1.3e+00

—

1.2e+00

1.4e+00

—

cases:27.15%

controls:23.71%

cases:19.21%

controls:9.07%

cases:4.64%

controls:1.26%

—

cases:4.64%

controls:1.39%

cases:27.27%

controls:8.34%

—

358

110

1152

137

122

1373

144

1491

—

144

1489

124

1362

—

Bicarbonate [Moles/volume] in Serum or Plasma
1963-8 [3016293]

—

2.3e+00

—

cases:6.82%

controls:0.74%

—

123

1475

—

Carbon dioxide [Partial pressure] in Arterial blood
2019-8 [3027946]

6.8e-01

—

1.0e+50

—

2.3e+00

—

cases:3.97%

controls:2.05%

—

cases:3.31%

controls:0.00%

—

cases:12.12%

controls:1.41%

—

145

1479

—

146

1510

—

116

1465

—

Oxygen [Partial pressure] in Arterial blood
2703-7 [3027801]

6.8e-01

—

1.0e+50

—

2.3e+00

—

cases:3.97%

controls:2.05%

—

cases:3.31%

controls:0.00%

—

cases:12.12%

controls:1.41%

—

145

1479

—

146

1510

—

116

1465

—

Normoblasts [#/volume] in Blood
715-3 [3021589]

9.1e-02

4.4e-01

1.3e+00

—

4.8e-01

9.1e-01

—

cases:11.92%

controls:10.99%

cases:15.23%

controls:10.33%

cases:8.61%

controls:2.38%

—

cases:4.64%

controls:2.91%

cases:24.24%

controls:11.44%

—

166

133

1344

156

128

1354

138

1474

—

144

1466

170

100

1316

—

Bicarbonate [Moles/volume] standard in Arterial blood
19230-2 [3014218]

1.7e+00

—

2.3e+00

—

cases:3.31%

controls:0.60%

—

cases:6.06%

controls:0.67%

—

146

1501

—

124

1476

—

pH of Arterial blood
2744-1 [3019977]

6.8e-01

—

2.2e+00

—

cases:3.97%

controls:2.05%

—

cases:11.36%

controls:1.35%

—

145

1479

—

117

1466

—

FEV1
20150-9 [3024653]

4.2e-01

—

2.2e+00

—

cases:3.97%

controls:2.65%

—

cases:5.30%

controls:0.61%

—

145

1470

—

125

1477

—

FEV1/FVC
19926-5 [3011505]

4.2e-01

—

2.2e+00

—

cases:3.97%

controls:2.65%

—

cases:5.30%

controls:0.61%

—

145

1470

—

125

1477

—

Forced vital capacity [Volume] Respiratory system
19870-5 [3020158]

4.2e-01

—

2.2e+00

—

cases:3.97%

controls:2.65%

—

cases:5.30%

controls:0.61%

—

145

1470

—

125

1477

—

CBC W Ordered Manual Differential panel - Blood
57782-5 [40760892]

2.8e-01

8.1e-01

2.0e+00

—

2.2e+00

8.8e-01

—

cases:7.28%

controls:5.63%

cases:7.95%

controls:3.71%

cases:3.31%

controls:0.46%

—

cases:3.97%

controls:0.46%

cases:8.33%

controls:3.63%

—

140

1425

139

1454

146

1503

—

145

1503

121

1432

—

Albumin [Mass/volume] in Serum or Plasma
1751-7 [3024561]

4.2e-01

1.1e+00

8.6e-01

—

1.1e+00

—

cases:15.89%

controls:11.06%

cases:19.21%

controls:7.48%

cases:3.97%

controls:1.72%

—

cases:18.18%

controls:7.00%

—

167

127

1343

113

122

1397

145

1484

—

104

108

1382

—

Oxygen saturation in Arterial blood
2708-6 [3016502]

6.7e-01

—

2.2e+00

—

cases:3.31%

controls:1.72%

—

cases:10.61%

controls:1.35%

—

146

1484

—

118

1466

—

Spirometry for bronchospasm with prolonged evaluation after bronchodilator
113016006 [4010399]

2.6e-01

—

2.2e+00

—

cases:3.31%

controls:2.58%

—

cases:6.06%

controls:0.74%

—

146

1471

—

124

1475

—

Monitoring the use of the aid
R5140 [2001310249]

—

2.2e+00

—

cases:9.09%

controls:1.14%

—

120

1469

—

Prealbumin [Mass/volume] in Serum or Plasma
14338-8 [3013742]

—

1.1e+00

—

2.1e+00

—

cases:3.31%

controls:1.13%

—

cases:7.58%

controls:1.01%

—

146

1493

—

122

1471

—

Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma
6768-6 [3035995]

3.5e-03

5.9e-01

1.3e+00

—

3.3e-01

7.1e-01

—

cases:25.83%

controls:25.76%

cases:25.83%

controls:16.16%

cases:13.91%

controls:4.11%

—

cases:4.64%

controls:3.38%

cases:28.79%

controls:16.55%

—

389

112

1121

244

112

1266

130

1448

—

144

1459

246

1240

—

buprenorphine; parenteral, sublingual, transdermal
N02AE01 [21604287]

—

2.0e+00

—

cases:6.82%

controls:0.94%

—

123

1472

—

erdosteine; oral
R05CB15 [21603394]

—

2.0e+00

—

cases:7.58%

controls:1.08%

—

122

1470

—

Methemoglobin/Hemoglobin.total in Arterial blood
2615-3 [3006217]

—

2.0e+00

—

cases:5.30%

controls:0.74%

—

125

1475

—

Gamma glutamyl transferase [Enzymatic activity/volume] in Serum or Plasma
2324-2 [3026910]

7.3e-02

7.4e-01

2.0e+00

—

4.5e-01

—

cases:21.19%

controls:20.00%

cases:19.21%

controls:10.20%

cases:8.61%

controls:1.26%

—

cases:15.15%

controls:10.23%

—

302

119

1208

154

122

1356

138

1491

—

152

112

1334

—

lactulose; oral
A06AD11 [21600571]

—

2.0e+00

—

cases:7.58%

controls:1.14%

—

122

1469

—

No procedures
SPAT1301 [2001700402]

1.2e-01

4.0e-01

—

1.9e+00

—

cases:6.62%

controls:5.89%

cases:3.31%

controls:2.25%

—

cases:10.61%

controls:1.68%

—

141

1421

146

1476

—

118

1461

—

Other specified special examinations
Z01.8 [45581003]

—

1.2e+00

—

1.9e+00

—

cases:3.31%

controls:0.99%

—

cases:5.30%

controls:0.81%

—

146

1495

—

125

1474

—

Carboxyhemoglobin/Hemoglobin.total in Arterial blood
2030-5 [3028653]

—

1.9e+00

—

cases:5.30%

controls:0.81%

—

125

1474

—

Hemoglobin [Mass/volume] in Arterial blood
30313-1 [3002173]

—

1.9e+00

—

cases:7.58%

controls:1.21%

—

122

1468

—

Emergency Room Visit
ER [9203]

-6.4e-02

7.6e-01

1.5e+00

—

1.1e+00

—

cases:33.77%

controls:35.23%

cases:22.52%

controls:11.99%

cases:3.97%

controls:0.93%

—

cases:23.48%

controls:9.22%

—

532

100

978

181

117

1329

145

1496

—

137

101

1349

—

oxycodone; oral, parenteral
N02AA05 [21604260]

—

-1.0e+50

1.9e+00

—

cases:0.00%

controls:0.46%

cases:10.61%

controls:1.82%

—

151

1503

118

1459

—

Fall on same level from slipping, tripping and stumbling
W01 [45756243]

1.1e-01

1.1e+00

—

1.8e+00

—

cases:4.64%

controls:4.17%

cases:3.97%

controls:1.32%

—

cases:8.33%

controls:1.41%

—

144

1447

145

1490

—

121

1465

—

Pneumonia, unspecified
J18.9 [45601123]

3.9e-01

—

1.8e+00

—

cases:4.64%

controls:3.18%

—

cases:6.06%

controls:1.01%

—

144

1462

—

124

1471

—

Chloride [Moles/volume] in Serum or Plasma
2075-0 [3014576]

—

1.8e+00

—

cases:8.33%

controls:1.48%

—

121

1464

—

Fractional oxyhemoglobin in Arterial blood
2714-4 [3014007]

—

1.8e+00

—

cases:5.30%

controls:0.94%

—

125

1472

—

Dyspnoea
R06.0 [45558449]

8.5e-01

1.8e+00

—

cases:9.27%

controls:4.17%

cases:8.61%

controls:1.59%

—

137

1447

138

1486

—

General Practice
1 [38004446]

-6.2e-02

6.3e-01

—

1.8e+00

—

cases:13.25%

controls:13.97%

cases:8.61%

controls:4.77%

—

cases:28.79%

controls:6.53%

—

211

131

1299

138

1438

—

1389

—

Rheumatoid factor [Units/volume] in Serum or Plasma
11572-5 [3021614]

3.7e-01

1.7e+00

—

cases:4.64%

controls:3.25%

cases:5.30%

controls:0.99%

—

144

1461

143

1495

—

Emergency Room and Inpatient Visit
ERIP [262]

—

3.9e-01

2.3e+00

—

1.7e+00

—

cases:4.64%

controls:3.18%

cases:3.31%

controls:0.33%

—

cases:15.15%

controls:3.16%

—

144

1462

146

1505

—

112

1439

—

HIV 1 and 2 tests - Meaningful Use set
75622-1 [46235355]

5.3e-01

1.7e+00

—

cases:5.30%

controls:3.18%

cases:6.62%

controls:1.32%

—

143

1462

141

1490

—

Spinal stenosis
M48.0 [45557888]

9.2e-01

1.7e+00

—

1.7e+00

—

cases:5.96%

controls:2.45%

cases:5.96%

controls:1.19%

—

cases:3.79%

controls:0.74%

—

142

1473

142

1492

—

127

1475

—

Cobalamin (Vitamin B12) [Moles/volume] in Serum or Plasma
14685-2 [3009035]

0.0e+00

1.6e+00

—

cases:5.96%

controls:5.96%

cases:8.61%

controls:1.85%

—

142

1420

138

1482

—

citalopram; oral, parenteral
N06AB04 [21604712]

—

9.8e-01

—

1.6e+00

—

cases:3.97%

controls:1.52%

—

cases:7.58%

controls:1.68%

—

145

1487

—

122

1461

—

Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma
1920-8 [3013721]

-1.1e-01

6.8e-01

1.7e+00

—

2.3e+00

1.6e+00

—

cases:8.61%

controls:9.54%

cases:7.28%

controls:3.84%

cases:4.64%

controls:0.86%

—

cases:3.31%

controls:0.33%

cases:18.18%

controls:4.44%

—

144

138

1366

140

1452

144

1497

—

146

1505

108

1420

—

Calcium [Moles/volume] in Serum or Plasma
2000-8 [3015377]

-2.3e-01

1.5e+00

—

8.2e-02

—

cases:6.62%

controls:8.21%

cases:14.57%

controls:3.84%

—

cases:3.79%

controls:3.50%

—

124

141

1386

129

1452

—

127

1434

—

Upper gastrointestinal surgery
106 [44777669]

-1.6e-01

3.0e-02

-1.0e+50

—

1.4e+00

—

cases:10.60%

controls:12.19%

cases:4.64%

controls:4.50%

cases:0.00%

controls:0.40%

—

cases:13.64%

controls:3.70%

—

184

135

1326

144

1442

151

1504

—

114

1431

—

Magnesium [Moles/volume] in Serum or Plasma
2601-3 [3012095]

7.2e-01

1.4e+00

—

1.0e+00

—

cases:5.30%

controls:2.65%

cases:6.62%

controls:1.72%

—

cases:6.06%

controls:2.29%

—

143

1470

141

1484

—

124

1452

—

Psychiatry
26 [38004469]

5.7e-01

9.2e-01

—

1.8e+00

1.4e+00

—

cases:7.28%

controls:4.24%

cases:5.30%

controls:2.19%

—

cases:3.97%

controls:0.66%

cases:7.58%

controls:2.02%

—

140

1446

143

1477

—

145

1500

122

1456

—

pH of Serum or Plasma
2753-2 [3018418]

4.6e-01

1.4e+00

—

-1.0e+50

-6.6e-02

—

cases:10.60%

controls:6.95%

cases:13.25%

controls:3.71%

—

cases:0.00%

controls:0.66%

cases:3.79%

controls:4.04%

—

105

135

1405

131

1454

—

151

1500

127

1426

—

Gastroenterology
10 [38004455]

-2.2e-01

2.1e-02

—

1.3e+00

—

cases:5.30%

controls:6.49%

cases:3.31%

controls:3.25%

—

cases:9.85%

controls:2.96%

—

143

1412

146

1461

—

119

1442

—

Treatment plan or consultation
WZC00 [2001310885]

-1.7e-01

—

-1.0e+50

—

1.3e+00

—

cases:5.30%

controls:6.23%

—

cases:0.00%

controls:0.46%

—

cases:9.85%

controls:2.96%

—

143

1416

—

151

1503

—

119

1442

—

escitalopram; oral
N06AB10 [21604718]

4.6e-01

—

1.3e+00

—

cases:4.64%

controls:2.98%

—

cases:9.09%

controls:2.76%

—

144

1465

—

120

1445

—

Other specified counselling
Z71.8 [45581061]

2.7e-01

1.3e+00

—

1.2e+00

—

cases:4.64%

controls:3.58%

cases:5.30%

controls:1.46%

—

cases:9.09%

controls:2.83%

—

144

1456

143

1488

—

120

1444

—

Otolaryngology
4 [38004449]

1.6e-01

1.2e+00

1.6e+00

—

2.3e+00

5.4e-01

—

cases:15.23%

controls:13.31%

cases:13.25%

controls:4.30%

cases:3.31%

controls:0.66%

—

cases:3.31%

controls:0.33%

cases:7.58%

controls:4.58%

—

201

128

1309

131

1445

146

1500

—

146

1505

122

1418

—

Neutrophils [#/volume] in Blood by Automated count
751-8 [3013650]

6.9e-02

3.8e-01

1.1e+00

—

9.6e-01

1.2e+00

—

cases:16.56%

controls:15.63%

cases:15.89%

controls:11.46%

cases:7.95%

controls:2.78%

—

cases:7.28%

controls:2.91%

cases:28.03%

controls:10.57%

—

236

126

1274

173

127

1337

139

1468

—

140

1466

157

1329

—

zopiclone; oral
N05CF01 [21604654]

-2.1e-01

5.3e-01

—

8.9e-01

1.2e+00

—

cases:6.62%

controls:8.08%

cases:8.61%

controls:5.23%

—

cases:3.31%

controls:1.39%

cases:13.64%

controls:4.58%

—

122

141

1388

138

1431

—

146

1489

114

1418

—

mirtazapine; oral
N06AX11 [21604740]

-1.1e-02

1.7e-01

—

1.2e+00

—

cases:6.62%

controls:6.69%

cases:5.30%

controls:4.50%

—

cases:12.88%

controls:4.31%

—

101

141

1409

143

1442

—

115

1422

—

Creatinine [Moles/volume] in Serum or Plasma
14682-9 [3020564]

-3.5e-02

4.2e-01

1.1e+00

—

7.0e-01

5.2e-01

—

cases:46.36%

controls:47.22%

cases:48.34%

controls:38.01%

cases:23.84%

controls:9.14%

—

cases:15.23%

controls:8.21%

cases:53.03%

controls:40.17%

—

713

797

574

936

138

115

1372

—

124

128

1386

597

889

—

Differential panel, method unspecified - Blood
69738-3 [42870588]

3.9e-01

7.4e-01

1.5e+00

—

1.0e+00

1.1e+00

—

cases:11.92%

controls:8.41%

cases:10.60%

controls:5.36%

cases:5.30%

controls:1.19%

—

cases:3.31%

controls:1.19%

cases:16.67%

controls:6.19%

—

127

133

1383

135

1429

143

1492

—

146

1492

110

1394

—

Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI)/1.73 sq M
62238-1 [40764999]

1.1e-01

4.3e-01

1.1e+00

—

8.6e-01

5.2e-01

—

cases:36.42%

controls:33.91%

cases:36.42%

controls:27.15%

cases:16.56%

controls:6.36%

—

cases:13.25%

controls:6.09%

cases:42.42%

controls:30.42%

—

512

998

410

1100

126

1414

—

131

1418

452

1034

—

tizanidine; oral
M03BX02 [21604116]

2.8e-01

1.1e+00

—

9.5e-01

—

cases:15.23%

controls:11.99%

cases:10.60%

controls:3.91%

—

cases:9.85%

controls:4.04%

—

181

128

1329

135

1451

—

119

1426

—

Erythrocyte sedimentation rate [Velocity] in Red Blood Cells by Westergren method
4537-7 [3013707]

2.3e-01

1.0e+00

1.2e+00

—

-6.6e-01

—

cases:29.14%

controls:24.70%

cases:29.14%

controls:12.65%

cases:5.96%

controls:1.85%

—

cases:6.82%

controls:12.45%

—

373

107

1137

191

107

1319

142

1482

—

185

123

1301

—

Telehealth
OMOP5556618 [722455]

2.6e-02

3.3e-01

1.0e+00

—

1.0e+00

—

cases:28.48%

controls:27.95%

cases:15.89%

controls:11.99%

cases:4.64%

controls:1.72%

—

cases:18.94%

controls:7.74%

—

422

108

1088

181

127

1329

144

1484

—

115

107

1371

—

Glucose [Moles/volume] in Serum or Plasma
14749-6 [3013826]

3.8e-01

5.1e-01

—

9.6e-01

—

cases:20.53%

controls:15.03%

cases:13.91%

controls:8.81%

—

cases:17.42%

controls:7.47%

—

227

120

1283

133

130

1377

—

111

109

1375

—

CBC panel - Blood by Automated count
58410-2 [40761511]

3.5e-02

1.3e-01

9.5e-01

—

5.5e-01

5.0e-01

—

cases:43.71%

controls:42.85%

cases:29.80%

controls:27.22%

cases:14.57%

controls:6.16%

—

cases:9.93%

controls:5.96%

cases:36.36%

controls:25.71%

—

647

863

411

106

1099

129

1417

—

136

1420

382

1104

—

Potassium [Moles/volume] in Serum or Plasma
2823-3 [3023103]

2.4e-02

4.5e-01

9.5e-01

—

-9.1e-02

4.7e-01

—

cases:44.37%

controls:43.77%

cases:43.71%

controls:33.18%

cases:16.56%

controls:7.15%

—

cases:5.96%

controls:6.49%

cases:46.97%

controls:35.60%

—

661

849

501

1009

108

126

1402

—

142

1412

529

957

—

Sodium [Moles/volume] in Serum or Plasma
2951-2 [3019550]

3.8e-02

4.7e-01

9.2e-01

—

-8.0e-02

4.9e-01

—

cases:44.37%

controls:43.44%

cases:43.71%

controls:32.65%

cases:15.89%

controls:7.02%

—

cases:5.96%

controls:6.42%

cases:46.97%

controls:35.20%

—

656

854

493

1017

106

127

1404

—

142

1413

523

963

—

Calcium.ionized [Moles/volume] in Serum or Plasma
1995-0 [3021347]

1.1e-01

8.7e-01

1.5e+00

—

6.4e-01

—

cases:13.25%

controls:12.05%

cases:14.57%

controls:6.69%

cases:3.31%

controls:0.73%

—

cases:12.12%

controls:6.80%

—

182

131

1328

101

129

1409

146

1499

—

101

116

1385

—

Emergency Medicine
93 [38004510]

-5.0e-01

4.4e-01

—

8.1e-01

—

cases:12.58%

controls:19.21%

cases:14.57%

controls:9.87%

—

cases:20.45%

controls:10.23%

—

290

132

1220

149

129

1361

—

152

105

1334

—

Thyrotropin [Units/volume] in Serum or Plasma
3016-3 [3009201]

-1.4e-01

7.3e-01

9.6e-01

—

-9.5e-01

—

cases:31.13%

controls:34.17%

cases:32.45%

controls:18.81%

cases:9.27%

controls:3.77%

—

cases:8.33%

controls:18.98%

—

516

104

994

284

102

1226

137

1453

—

282

121

1204

—

Thyroxine (T4) free [Moles/volume] in Serum or Plasma
14920-3 [3008486]

-2.0e-01

7.2e-01

7.9e-01

—

-7.9e-01

—

cases:23.18%

controls:26.95%

cases:23.84%

controls:13.18%

cases:5.96%

controls:2.78%

—

cases:6.06%

controls:12.45%

—

407

116

1103

199

115

1311

142

1468

—

185

124

1301

—

C reactive protein [Mass/volume] in Serum or Plasma
1988-5 [3020460]

1.3e-01

5.3e-01

9.0e-01

—

2.4e-01

7.2e-01

—

cases:40.40%

controls:37.28%

cases:34.44%

controls:23.58%

cases:11.92%

controls:5.23%

—

cases:5.96%

controls:4.77%

cases:40.15%

controls:24.63%

—

563

947

356

1154

133

1431

—

142

1438

366

1120

—

Occlusion and stenosis of carotid artery
I65.2 [45552808]

-1.0e+50

—

cases:0.00%

controls:0.33%

—

151

1505

—

Body height measure
50373000 [4177340]

-4.6e-01

-1.0e-01

—

1.0e+50

—

cases:17.22%

controls:24.83%

cases:6.62%

controls:7.28%

—

cases:6.06%

controls:0.00%

—

375

125

1135

110

141

1400

—

124

1486

—

Operation for osteochondritis of knee, arthroscopic
NGF25 [2001308133]

-1.0e+50

—

cases:0.00%

controls:0.53%

—

151

1502

—

hydrocortisone and antiinfectives
S03CA04 [21605208]

—

-1.0e+50

—

cases:0.00%

controls:0.94%

—

132

1472

—

ramipril; oral
C09AA05 [21601789]

-6.8e-01

-7.4e-01

—

cases:4.64%

controls:8.74%

cases:3.97%

controls:8.01%

—

132

144

1378

121

145

1389

—

Kuhnt-Junius degeneration
H35.30 [2000502314]

—

-1.0e+50

—

cases:0.00%

controls:0.81%

—

132

1474

—

candesartan; oral
C09CA06 [21601829]

6.6e-02

3.5e-01

—

8.7e-02

—

cases:6.62%

controls:6.23%

cases:7.28%

controls:5.23%

—

cases:6.06%

controls:5.59%

—

141

1416

140

1431

—

124

1403

—

One hour or less
ZXE00 [2001311394]

-2.1e-01

—

cases:5.96%

controls:7.28%

—

110

142

1400

—

rosuvastatin; oral
C10AA07 [21601862]

5.5e-02

-1.9e-01

—

-9.0e-01

—

cases:6.62%

controls:6.29%

cases:5.96%

controls:7.15%

—

cases:3.79%

controls:8.82%

—

141

1415

108

142

1402

—

131

127

1355

—

metronidazole and furazolidone
P01AB51 [45893518]

-1.0e+50

—

cases:0.00%

controls:0.66%

—

151

1500

—

Gastro-oesophageal reflux disease without oesophagitis
K21.9 [45538509]

9.9e-01

—

cases:3.31%

controls:1.26%

—

146

1491

—

Primary total prosthetic replacement of hip joint not using cement
NFB30 [2001307921]

-1.0e+50

—

cases:0.00%

controls:1.26%

—

151

1491

—

Electrocardiogram with exercise test
46136006 [4261794]

—

-1.0e+50

—

-1.0e+50

—

cases:0.00%

controls:0.40%

—

cases:0.00%

controls:0.34%

—

151

1504

—

132

1481

—

Pap smear
SPAT1193 [2001700294]

-1.0e+50

—

cases:0.00%

controls:1.19%

cases:0.00%

controls:0.33%

—

151

1492

151

1505

—

Influenza virus B RNA [Presence] in Specimen by NAA with probe detection
40982-1 [3038288]

-1.0e+50

—

1.6e+00

—

cases:0.00%

controls:1.59%

cases:0.00%

controls:0.53%

—

cases:5.30%

controls:1.14%

—

151

1486

151

1502

—

125

1469

—

Flexible sigmoidoscopy with biopsy
UJF45 [2001305031]

—

-1.0e+50

—

-1.0e+50

—

cases:0.00%

controls:0.33%

—

cases:0.00%

controls:0.34%

—

151

1505

—

132

1481

—

Folate [Moles/volume] in Red Blood Cells
14731-4 [3019309]

-2.2e-01

1.2e+00

—

cases:3.97%

controls:4.90%

cases:4.64%

controls:1.46%

—

145

1436

144

1488

—

etodolac; oral
M01AB08 [21603948]

-1.0e+50

—

cases:0.00%

controls:0.73%

—

151

1499

—

Fibromyalgia
M79.7 [45553272]

-1.0e+50

—

cases:0.00%

controls:0.40%

—

151

1504

—

SMOKING - SMOKE2: no - SMOKE3: former - SMOKE5: Unspecified
SMOKING-2-2-0 [2002330110]

-2.2e-01

—

cases:3.31%

controls:4.11%

—

146

1448

—

Paraesthesia of skin
R20.2 [45568120]

—

-1.0e+50

—

cases:0.00%

controls:0.47%

—

132

1479

—

montelukast; oral
R03DC03 [21603356]

2.1e-02

—

-1.0e+50

—

cases:3.31%

controls:3.25%

—

cases:0.00%

controls:0.53%

—

146

1461

—

151

1502

—

Cone beam CT of paranasal sinus
DM1AI [2001301744]

-1.0e+50

—

cases:0.00%

controls:0.46%

—

151

1503

—

Ulcerative colitis, unspecified
K51.9 [45605941]

-1.0e+50

—

cases:0.00%

controls:0.46%

—

151

1503

—

pimecrolimus
D11AH02 [21602339]

-1.0e+50

—

cases:0.00%

controls:0.66%

—

151

1500

—

SMOKING - SMOKE2: no - SMOKE3: never - SMOKE5: never
SMOKING-2-3-5 [2002330114]

—

-1.0e+50

—

cases:0.00%

controls:0.53%

—

151

1502

—

Oxygen [Partial pressure] in Venous blood
2705-2 [3024354]

—

-1.0e+50

—

cases:0.00%

controls:0.40%

—

151

1504

—

Impacted cerumen
H61.2 [45562307]

—

-1.0e+50

—

cases:0.00%

controls:0.67%

—

132

1476

—

Complement+Immunoglobulin [Units/volume] in Red Blood Cells
4533-6 [3024403]

—

-1.0e+50

—

cases:0.00%

controls:0.33%

—

151

1505

—

Chronic glaucoma with open ventricular angle
H40.13 [2000502335]

—

-1.0e+50

—

cases:0.00%

controls:0.67%

—

132

1476

—

dexamethasone
S03BA01 [21605201]

4.3e-01

—

cases:5.30%

controls:3.51%

—

143

1457

—

prazosin; oral
C02CA01 [21600411]

-1.0e+50

—

-1.0e+50

—

cases:0.00%

controls:0.60%

cases:0.00%

controls:0.40%

—

cases:0.00%

controls:0.47%

—

151

1501

151

1504

—

132

1479

—

Hypersensitivity skin testing
268377001 [4147813]

-1.0e+50

—

cases:0.00%

controls:0.66%

—

151

1500

—

moxonidine; oral
C02AC05 [21600401]

—

-1.0e+50

—

-1.0e+50

—

cases:0.00%

controls:0.79%

—

cases:0.00%

controls:0.33%

cases:0.00%

controls:0.54%

—

151

1498

—

151

1505

132

1478

—

Borrelia burgdorferi Ab [Presence] in Cerebral spinal fluid
22118-4 [3011166]

—

1.0e+50

—

cases:7.28%

controls:0.00%

—

140

1510

—

Observation for suspected disease or condition, unspecified
Z03.9 [45552062]

6.4e-02

—

cases:3.31%

controls:3.11%

—

146

1463

—

Prostate cancer
116 [2001600116]

—

-1.0e+50

—

cases:0.00%

controls:0.33%

—

151

1505

—

Restoration involving the entire crown of the tooth
SFA40 [2001310361]

3.6e-01

—

cases:6.62%

controls:4.70%

—

141

1439

—

IgG [Mass/volume] in Cerebral spinal fluid
2464-6 [3007368]

—

1.0e+50

—

cases:6.62%

controls:0.00%

—

141

1510

—

ketoprofen, combinations
M01AE53 [21603985]

-1.0e+50

—

cases:0.00%

controls:0.46%

—

151

1503

—

Hyaline casts [#/volume] in Urine by Automated count
51484-4 [3030981]

8.4e-01

—

cases:3.31%

controls:1.46%

—

146

1488

—

Ear pain/earache
H01 [2002000475]

-1.0e+50

—

-1.0e+50

—

cases:0.00%

controls:1.39%

cases:0.00%

controls:0.60%

—

cases:0.00%

controls:0.61%

—

151

1489

151

1501

—

132

1477

—

Doppler ultrasound examination of heart
FM1DE [2001303299]

-1.0e+50

—

cases:0.00%

controls:1.52%

cases:0.00%

controls:0.53%

—

151

1487

151

1502

—

ephedrine; oral
R03CA02 [21603304]

-1.0e+50

—

cases:0.00%

controls:0.33%

—

151

1505

—

Clinical & Laboratory Dermatological Immunology Physician
207NI0002X [38003841]

4.6e-02

—

-1.0e+50

—

cases:7.95%

controls:7.62%

—

cases:0.00%

controls:0.40%

—

115

139

1395

—

151

1504

—

Emergency treatment
SGA01 [2001310379]

4.2e-02

-1.0e+50

—

-1.0e+50

—

cases:3.31%

controls:3.18%

cases:0.00%

controls:0.53%

—

cases:0.00%

controls:0.34%

—

146

1462

151

1502

—

132

1481

—

digoxin; oral, parenteral
C01AA05 [21600234]

—

-1.0e+50

—

cases:0.00%

controls:0.46%

—

151

1503

—

Measurement of blood pressure with Doppler ultrasound device
SPAT1099 [2001700200]

-1.0e+50

—

cases:0.00%

controls:0.40%

—

151

1504

—

Hemoglobin [Presence] in Urine by Test strip
5794-3 [3011397]

-1.4e-01

-2.1e-01

-1.0e+50

—

-1.0e+50

—

cases:4.64%

controls:5.30%

cases:3.31%

controls:4.04%

cases:0.00%

controls:0.40%

—

cases:0.00%

controls:0.33%

—

144

1430

146

1449

151

1504

—

151

1505

—

Cystitis
N30 [45563012]

—

-1.0e+50

—

cases:0.00%

controls:0.40%

—

151

1504

—

Oxygen saturation in Venous blood
2711-0 [3024928]

—

-1.0e+50

—

cases:0.00%

controls:0.33%

—

151

1505

—

Buprenorphine [Presence] in Urine by Screen method
93494-3 [1001926]

-1.0e+50

—

cases:0.00%

controls:0.33%

—

151

1505

—

CT angiography of neck and brain
PA7BD [2001300235]

-1.0e+50

—

cases:0.00%

controls:0.33%

—

151

1505

—

Dog dander IgE Ab [Units/volume] in Serum
6098-8 [3014133]

-1.0e+50

—

cases:0.00%

controls:0.40%

—

151

1504

—

opium derivatives and expectorants
R05FA02 [21603439]

—

-1.0e+50

—

cases:0.00%

controls:0.40%

—

151

1504

—

Use of symptom diary
SPAT1359 [2001700460]

-1.0e+50

—

cases:0.00%

controls:0.60%

—

151

1501

—

Lichen sclerosus et atrophicus
L90.0 [45548221]

-1.0e+50

—

cases:0.00%

controls:0.33%

—

151

1505

—

Coronary artery bypass surgery
11 [2002100102]

-1.0e+50

—

cases:0.00%

controls:0.40%

—

151

1504

—

levomepromazine; oral, parenteral
N05AA02 [21604493]

-1.0e+50

—

cases:0.00%

controls:0.40%

—

151

1504

—

Contusion of knee
S80.0 [45569633]

-1.0e+50

—

cases:0.00%

controls:0.53%

—

151

1502

—

FEV1 percent change
69983-5 [42868472]

5.9e-01

—

cases:3.97%

controls:2.25%

—

145

1476

—

Oedema, unspecified
R60.9 [45568143]

-1.0e+50

—

cases:0.00%

controls:0.33%

—

151

1505

—

Bacteria identified in Blood by Culture
600-7 [3023368]

-3.5e-01

—

-1.0e+50

—

1.1e+00

—

cases:3.97%

controls:5.56%

—

cases:0.00%

controls:0.33%

—

cases:6.06%

controls:2.15%

—

145

1426

—

151

1505

—

124

1454

—

levofloxacin
S01AE05 [43534860]

3.7e-01

—

cases:3.31%

controls:2.32%

—

146

1475

—

methylprednisolone
D07AA01 [21602101]

-1.0e+50

—

cases:0.00%

controls:0.53%

—

151

1502

—

Urinalysis microscopic panel [#/volume] - Urine by Automated count
50554-5 [3029287]

-7.0e-02

1.6e-01

—

3.8e-01

—

cases:7.95%

controls:8.48%

cases:4.64%

controls:3.97%

—

cases:6.82%

controls:4.78%

—

128

139

1382

144

1450

—

123

1415

—

Endomysium IgA Ab [Titer] in Serum
10863-9 [3020961]

—

-1.0e+50

—

cases:0.00%

controls:0.40%

—

151

1504

—

Chronic respiratory failure
J96.1 [45557632]

—

1.0e+50

—

1.0e+50

—

cases:3.97%

controls:0.00%

—

cases:3.97%

controls:0.00%

—

145

1510

—

145

1510

—

HIV 1 RNA [Units/volume] (viral load) in Serum or Plasma by Probe with amplification
10351-5 [3013180]

—

-1.0e+50

—

-1.0e+50

—

cases:0.00%

controls:0.33%

—

cases:0.00%

controls:0.34%

—

151

1505

—

132

1481

—

Pain in joint
M25.5 [45586941]

3.5e-01

7.9e-01

—

-1.0e+50

—

cases:7.28%

controls:5.23%

cases:3.31%

controls:1.52%

—

cases:0.00%

controls:1.95%

—

140

1431

146

1487

—

132

1457

—

pneumococcus, purified polysaccharides antigen
J07AL01 [21601312]

-1.0e+50

—

cases:0.00%

controls:0.53%

—

151

1502

—

Cystostatic therapy of methastized malignancy
WD105 [2001310678]

-1.0e+50

—

cases:0.00%

controls:0.40%

cases:0.00%

controls:0.46%

cases:0.00%

controls:0.33%

—

151

1504

151

1503

151

1505

—

Fibrin D-dimer FEU [Mass/volume] in Platelet poor plasma
48065-7 [3051714]

6.3e-01

—

cases:9.27%

controls:5.17%

—

137

1432

—

Influenza due to identified zoonotic or pandemic influenza virus
J09 [45755449]

-1.0e+50

—

cases:0.00%

controls:0.33%

—

151

1505

—

Infiltration anesthesia
WX110 [2001310767]

-4.2e-02

-1.2e-01

—

-6.7e-01

—

cases:21.85%

controls:22.58%

cases:7.28%

controls:8.15%

—

cases:4.55%

controls:8.55%

—

341

118

1169

123

140

1387

—

127

126

1359

—

Eye pressure measurement
XCH00 [2001301234]

-1.0e+50

—

cases:0.00%

controls:0.46%

cases:0.00%

controls:0.33%

—

151

1503

151

1505

—

Three-surface restoration
SFA30 [2001310360]

-6.0e-01

-2.4e-01

—

-1.0e+50

—

cases:5.96%

controls:10.40%

cases:3.31%

controls:4.17%

—

cases:0.00%

controls:0.40%

—

157

142

1353

146

1447

—

151

1504

—

nystatin; oral
A07AA02 [21600604]

-1.0e+50

—

cases:0.00%

controls:0.86%

cases:0.00%

controls:0.40%

—

151

1497

151

1504

—

doxepin; oral, parenteral
N06AA12 [21604699]

—

-1.0e+50

—

cases:0.00%

controls:0.34%

—

132

1481

—

fluticasone furoate; nasal
R01AD12 [21605053]

7.2e-02

7.3e-01

—

5.6e-01

—

cases:10.60%

controls:9.93%

cases:6.62%

controls:3.31%

—

cases:6.06%

controls:3.57%

—

150

135

1360

141

1460

—

124

1433

—

Unstable angina
I20.09 [2000502389]

-1.0e+50

—

cases:0.00%

controls:0.86%

—

151

1497

—

Caries limited to enamel
K02.0 [45576967]

—

-1.0e+50

—

cases:0.00%

controls:0.46%

—

151

1503

—

Osteoporosis, unspecified
M81.9 [45591963]

—

-1.0e+50

—

-1.0e+50

—

cases:0.00%

controls:0.40%

—

cases:0.00%

controls:0.40%

—

151

1504

—

132

1480

—

telmisartan and diuretics
C09DA07 [21601839]

-1.0e+50

—

-1.0e+50

—

cases:0.00%

controls:0.46%

cases:0.00%

controls:0.40%

—

cases:0.00%

controls:0.54%

—

151

1503

151

1504

—

132

1478

—

Cathetrisation of vein
TPH04 [2001309597]

—

-1.0e+50

—

cases:0.00%

controls:1.26%

—

151

1491

—

codeine and ibuprofen
N02AJ08 [1123631]

-1.0e+50

—

cases:0.00%

controls:0.46%

—

151

1503

—

leuprorelin; implant, parenteral
L02AE02 [21603825]

-1.0e+50

—

cases:0.00%

controls:0.40%

cases:0.00%

controls:0.33%

—

151

1504

151

1505

—

diclofenac; oral, parenteral, rectal
M01AB05 [21603945]

3.7e-01

4.7e-01

—

-2.9e-01

—

cases:21.85%

controls:16.16%

cases:7.95%

controls:5.10%

—

cases:3.79%

controls:4.98%

—

244

118

1266

139

1433

—

127

1412

—

antibiotics in combination with corticosteroids
D01AA20 [21601918]

—

-1.0e+50

—

cases:0.00%

controls:0.40%

—

132

1480

—

terbinafine; oral
D01BA02 [21601967]

6.2e-01

—

cases:5.96%

controls:3.31%

—

142

1460

—

Elbow X-ray examination without contrast
NC1AA [2001307421]

-1.0e+50

—

cases:0.00%

controls:0.33%

—

151

1505

—

Mucopurulent conjunctivitis
H10.0 [45596007]

—

-1.0e+50

—

cases:0.00%

controls:0.40%

—

151

1504

—

ketoprofen; ointment
M02AA10 [21604046]

—

-1.0e+50

—

-1.0e+50

—

cases:0.00%

controls:0.66%

—

cases:0.00%

controls:1.14%

—

151

1500

—

132

1469

—

Anaemia vit B12/folate deficiency
B81 [2002000292]

—

-1.0e+50

—

cases:0.00%

controls:0.53%

—

151

1502

—

Visual field testing with Octopus automated perimetry
CS444 [2001301477]

-1.0e+50

—

cases:0.00%

controls:0.60%

—

151

1501

—

Postmenopausal bleeding
N95.0 [45567872]

-1.0e+50

—

-1.0e+50

—

cases:0.00%

controls:0.86%

—

cases:0.00%

controls:0.47%

—

151

1497

—

132

1479

—

Suture or reinsertation of rotator cuff of shoulder
NBL00 [2001307341]

-1.0e+50

—

cases:0.00%

controls:0.40%

—

151

1504

—

rivaroxaban; oral
B01AF01 [43534761]

—

-1.0e+50

—

-1.0e+50

—

cases:0.00%

controls:1.85%

cases:0.00%

controls:0.79%

—

cases:0.00%

controls:0.79%

—

151

1482

151

1498

—

151

1498

—

Cells panel - Urine sediment
58434-2 [40761535]

-1.0e+50

—

cases:0.00%

controls:2.52%

—

151

1472

—

furosemide; oral, parenteral
C03CA01 [21601518]

—

-1.0e+50

—

-3.7e-01

—

cases:0.00%

controls:1.79%

—

cases:4.55%

controls:6.46%

—

151

1483

—

126

1390

—

Medicine administration
WVA20 [2001310740]

—

-1.0e+50

—

cases:0.00%

controls:0.40%

—

132

1480

—

Interscalenous plexus blockade
WX200 [2001310777]

-1.0e+50

—

cases:0.00%

controls:0.33%

—

151

1505

—

Demanding operative extraction of tooth
EBA12 [2001301926]

-1.0e+50

—

cases:0.00%

controls:0.33%

—

151

1505

—

Emergency visit or other similar visit involving procedures
WYA05 [2001310871]

2.2e-01

—

-1.0e+50

—

cases:11.92%

controls:9.80%

—

cases:0.00%

controls:0.33%

cases:0.00%

controls:1.01%

—

148

133

1362

—

151

1505

132

1471

—

fluconazole; oral, parenteral
J02AC01 [21603080]

—

-1.0e+50

—

-1.0e+50

—

cases:0.00%

controls:0.40%

—

cases:0.00%

controls:1.75%

—

151

1504

—

132

1460

—

metronidazole
D06BX01 [21602096]

-1.0e+50

—

-1.0e+50

—

cases:0.00%

controls:2.38%

cases:0.00%

controls:0.60%

—

cases:0.00%

controls:0.74%

—

151

1474

151

1501

—

132

1475

—

Abrasion dentifrice of teeth
K03.11 [2000502670]

-1.0e+50

—

cases:0.00%

controls:0.33%

—

151

1505

—

Spinal muscular atrophy and related syndromes
G12 [45600770]

—

1.0e+50

—

cases:5.30%

controls:0.00%

—

125

1486

—

mupirocin; nasal
R01AX06 [21603201]

1.4e+00

—

cases:3.31%

controls:0.86%

—

146

1497

—

Rheumatoid arthritis, unspecified
M06.9 [45533705]

-1.0e+50

—

cases:0.00%

controls:0.46%

—

151

1503

—

Benign paroxysmal vertigo
H81.1 [45572061]

—

-1.0e+50

—

cases:0.00%

controls:0.40%

—

132

1480

—

alfacalcidol; oral, parenteral
A11CC03 [21600818]

-1.0e+50

—

-1.0e+50

—

cases:0.00%

controls:0.40%

cases:0.00%

controls:0.33%

—

cases:0.00%

controls:0.40%

—

151

1504

151

1505

—

132

1480

—

Rectocele
N81.6 [45543893]

-1.0e+50

—

cases:0.00%

controls:0.86%

—

151

1497

—

Intravenous sedation or analgesia without general anesthesia
WX006 [2001310762]

-1.0e+50

—

-1.0e+50

—

cases:0.00%

controls:0.33%

—

cases:0.00%

controls:0.34%

—

151

1505

—

132

1481

—

Alveolitis of jaws
K10.3 [45591576]

-1.0e+50

—

cases:0.00%

controls:0.33%

—

151

1505

—

Extensive global examination
SPAT1360 [2001700461]

-1.0e+50

—

cases:0.00%

controls:0.93%

cases:0.00%

controls:0.33%

—

151

1496

151

1505

—

Anterior colporraphy with sutures for primary cystocele
LEF00 [2001306704]

-1.0e+50

—

cases:0.00%

controls:0.40%

—

151

1504

—

Helicobacter pylori Ab [Presence] in Serum
22310-7 [3038177]

-1.0e+50

—

cases:0.00%

controls:0.66%

—

151

1500

—

Total cardiopulmonary bypass in normothermia or moderate hypothermia at concurrent surgical procedure
FXA00 [2001303347]

-1.0e+50

—

cases:0.00%

controls:0.40%

—

151

1504

—

Moderate depressive episode
F32.1 [45552478]

-1.0e+50

—

cases:0.00%

controls:0.60%

—

151

1501

—

trazodone; oral
N06AX05 [21604734]

-1.0e+50

—

cases:0.00%

controls:0.33%

—

151

1505

—

Blood type and Crossmatch panel - Blood
34531-4 [3044640]

3.2e-01

—

7.3e-01

—

cases:11.26%

controls:8.41%

—

cases:5.30%

controls:2.62%

—

127

134

1383

—

125

1447

—

Geriatric Psychiatry
27 [38004470]

-1.0e+50

—

cases:0.00%

controls:0.40%

—

151

1504

—

prednisolone; oral, parenteral
H02AB06 [21602734]

-1.4e-01

6.7e-01

—

-1.0e+50

1.5e-01

—

cases:11.26%

controls:12.78%

cases:9.93%

controls:5.36%

—

cases:0.00%

controls:0.60%

cases:6.06%

controls:5.25%

—

193

134

1317

136

1429

—

151

1501

124

1408

—

Iron deficiency anaemia, unspecified
D50.9 [45605373]

-1.0e+50

—

cases:0.00%

controls:1.06%

—

151

1494

—

Overexertion and strenuous or repetitive movements
X50 [45756406]

-1.0e+50

—

cases:0.00%

controls:0.40%

—

151

1504

—

Cardiac arrhythmia NOS
K80 [2002000607]

—

-1.0e+50

—

-1.0e+50

—

cases:0.00%

controls:0.60%

—

cases:0.00%

controls:0.61%

—

151

1501

—

132

1477

—

metronidazole; vaginal
G01AF01 [21602392]

-1.0e+50

—

-1.0e+50

—

cases:0.00%

controls:2.72%

cases:0.00%

controls:0.66%

—

cases:0.00%

controls:0.81%

—

151

1469

151

1500

—

132

1474

—

Psoriasis vulgaris
L40.0 [45543370]

-1.0e+50

—

cases:0.00%

controls:0.66%

cases:0.00%

controls:0.53%

—

151

1500

151

1502

—

Fever
A03 [2002000144]

5.2e-01

—

-1.0e+50

—

cases:3.31%

controls:1.99%

—

cases:0.00%

controls:0.61%

—

146

1480

—

132

1477

—

norethisterone; oral
G03DC02 [21602553]

—

-1.0e+50

—

cases:0.00%

controls:0.60%

—

151

1501

—

Streptococcal tonsillitis
J03.0 [45601114]

-1.0e+50

—

cases:0.00%

controls:0.33%

—

151

1505

—

tadalafil; oral
G04BE08 [21602653]

—

-1.0e+50

—

-1.0e+50

—

cases:0.00%

controls:0.60%

—

cases:0.00%

controls:0.46%

—

151

1501

—

151

1503

—

Cardiac ultrasound examination through oesophagus
FM1BE [2001303285]

-1.0e+50

—

cases:0.00%

controls:1.19%

cases:0.00%

controls:0.60%

—

151

1492

151

1501

—

isosorbide mononitrate; oral
C01DA14 [21600324]

-2.7e-01

-6.0e-02

—

cases:3.97%

controls:5.17%

cases:3.31%

controls:3.51%

—

145

1432

146

1457

—

Guidance related to psychoactive substances / risk behaviour
SPAT1309 [2001700410]

-1.0e+50

—

cases:0.00%

controls:0.40%

—

151

1504

—

ketoprofen; oral, parenteral, rectal
M01AE03 [21603969]

-1.5e-01

—

-1.0e+50

—

cases:3.97%

controls:4.57%

—

cases:0.00%

controls:0.33%

—

145

1441

—

151

1505

—

Malignant neoplasm: Upper-outer quadrant of breast
C50.4 [45561816]

-1.0e+50

—

cases:0.00%

controls:0.46%

—

151

1503

—

Simple examination of mouth
SAA01 [2001310274]

7.0e-02

-3.3e-01

-1.0e+50

—

-7.2e-01

—

cases:25.83%

controls:24.50%

cases:9.27%

controls:12.45%

cases:0.00%

controls:0.99%

—

cases:6.82%

controls:13.06%

—

370

112

1140

188

137

1322

151

1495

—

194

123

1292

—

linagliptin; oral
A10BH05 [40251691]

-1.0e+50

—

cases:0.00%

controls:0.93%

—

151

1496

—

tramadol; oral, parenteral, rectal
N02AX02 [21604298]

-2.8e-02

-3.4e-01

—

7.5e-01

—

cases:10.60%

controls:10.86%

cases:3.31%

controls:4.57%

—

cases:6.06%

controls:2.96%

—

164

135

1346

146

1441

—

124

1442

—

Cystitis, unspecified
N30.9 [45606488]

-1.0e+50

—

cases:0.00%

controls:0.46%

—

151

1503

—

Lutropin [Units/volume] in Serum or Plasma
10501-5 [3009214]

-1.0e+50

—

cases:0.00%

controls:0.66%

cases:0.00%

controls:0.33%

—

151

1500

151

1505

—

LabWAS

↥

N Cases

N Controls

-log₁₀(p)

cases

controls

cases

controls

unit

-log₁₀(p)

N cases

N controls

(3023602) Cholesterol in HDL [Moles/volume] in Serum or Plasma

1240

0.23

18.23

3.1

5.5

1.47

1.44

mmol/l

0.26

1138

(3019900) Cholesterol [Moles/volume] in Serum or Plasma

1245

0.23

18.08

3.0

5.6

4.80

4.56

mmol/l

0.94

1152

(3001308) Cholesterol in LDL [Moles/volume] in Serum or Plasma

1266

0.23

17.63

3.3

6.4

2.82

2.65

mmol/l

0.73

1168

(3004410) Hemoglobin A1c/Hemoglobin.total in Blood

1210

0.27

13.92

4.2

6.9

36.28

40.22

mmol/mol

8.63

1138

(3048773) Triglyceride [Moles/volume] in Serum or Plasma --fasting

1194

0.28

13.73

2.7

4.6

1.18

1.31

mmol/l

1.13

1090

(40759883) Oligoclonal Bands IgG [Presence] in Cerebral spinal fluid by Isoelectric focusing

31.63

13.28

1.0

—

(3011166) Borrelia burgdorferi Ab [Presence] in Cerebral spinal fluid

17.22

11.13

1.0

1.1

—

(3010380) Borrelia burgdorferi IgG Ab [Units/volume] in Cerebral spinal fluid

14.55

10.45

1.0

1.2

—

(3014973) Borrelia burgdorferi IgM Ab [Units/volume] in Cerebral spinal fluid

13.51

10.14

1.0

1.1

—

(3044290) Cell count panel - Cerebral spinal fluid

9.43

9.93

1.0

1.3

—

(3018251) Fasting glucose [Moles/volume] in Serum or Plasma

1228

0.33

9.71

3.4

5.6

5.83

6.04

mmol/l

1.68

1130

(3016543) Leukocytes [#/volume] in Cerebral spinal fluid

8.23

9.62

1.0

1.2

1.54

2.78

e6/l

0.62

(3027475) Erythrocytes [#/volume] in Cerebral spinal fluid

7.69

9.23

1.0

1.3

134.36

231.05

e6/l

0.17

(1616796) Gas panel - Central venous blood

5.39

8.61

4.8

2.6

—

(3019060) Gas panel - Arterial blood

101

3.46

7.59

2.8

9.2

—

(3004588) Protein electrophoresis panel - Serum or Plasma

102

3.42

7.48

1.5

2.6

—

(3012516) Albumin [Mass/volume] in Urine

468

0.26

6.62

2.8

3.4

9.95

45.17

mg/l

3.71

315

(3027946) Carbon dioxide [Partial pressure] in Arterial blood

186

2.74

6.59

4.0

9.9

6.24

5.10

kpa

2.20

178

(3023465) Gamma globulin [Mass/volume] in Serum or Plasma by Electrophoresis

3.96

6.57

1.6

2.5

10.92

10.74

g/l

0.04

(3020682) Albumin/Creatinine [Ratio] in Urine

481

0.29

6.24

3.6

4.1

2.70

7.71

mg/mmol

1.59

311

(3027801) Oxygen [Partial pressure] in Arterial blood

186

2.65

6.10

4.1

9.9

12.17

12.21

kpa

0.02

178

(3017569) Oxygen content in Arterial blood

15.83

5.98

2.0

1.3

17.43

16.35

—

(3021601) Nitrite [Presence] in Urine by Test strip

717

0.40

5.92

3.0

4.2

0.00

estimate

-0.00

157

(3035350) Ketones [Presence] in Urine by Test strip

723

0.42

5.44

3.0

4.2

0.00

10.15

estimate

0.50

160

(3023410) Appearance of Cerebral spinal fluid

7.81

5.24

1.0

1.3

—

(3009261) Glucose [Presence] in Urine by Test strip

727

0.43

5.24

2.9

4.2

0.00

estimate

-0.00

145

(3022313) Gas panel - Capillary blood

3.36

4.99

5.1

4.0

—

(1761868) Lipid panel - Serum or Plasma

510

0.37

4.95

2.2

3.6

—

(3029379) Protein.monoclonal band 4 [Mass/volume] in Serum or Plasma by Electrophoresis

3.86

4.90

1.9

2.9

0.00

g/l

-0.00

(3019977) pH of Arterial blood

185

2.41

4.79

4.7

10.1

7.41

7.42

0.20

111

(3029713) Protein.monoclonal band 1 [Mass/volume] in Serum or Plasma by Electrophoresis

3.49

4.78

1.8

2.8

1.86

0.52

g/l

0.31

(3020891) Body temperature

3.09

4.78

3.0

4.6

36.95

36.93

°c

0.11

(3016502) Oxygen saturation in Arterial blood

166

2.44

4.66

4.0

10.5

94.67

95.54

0.29

161

(3003129) Base excess in Capillary blood by calculation

7.89

4.42

3.1

2.8

3.72

0.48

mmol/l

—

(3015736) pH of Urine

565

0.43

4.26

2.2

3.9

6.42

6.16

0.69

332

(3029338) Protein.monoclonal band 3 [Mass/volume] in Serum or Plasma by Electrophoresis

3.43

4.18

1.9

2.7

0.00

g/l

-0.00

(40763086) Leukocyte esterase [Presence] in Urine by Automated test strip

550

0.43

4.16

2.7

4.2

0.00

estimate

-0.00

131

(40768804) Tissue Pathology biopsy report

515

0.42

4.13

1.9

2.1

—

(40761511) CBC panel - Blood by Automated count

108

1273

0.47

3.99

10.9

16.5

—

(3016018) Differential panel - Cerebral spinal fluid

6.97

3.72

1.0

1.1

—

(3013603) Prostate specific Ag [Mass/volume] in Serum or Plasma

566

0.48

3.43

3.4

5.7

14.56

2.29

ug/l

0.46

510

(3029937) Albumin [Presence] in Urine by Test strip

422

0.44

3.24

3.1

4.0

0.00

estimate

-0.00

144

(3005013) Prostate Specific Ag Free [Mass/volume] in Serum or Plasma

348

0.40

3.21

2.3

3.3

0.95

0.84

ug/l

0.13

235

(3024135) Streptococcus.beta-hemolytic [Presence] in Throat by Organism specific culture

175

0.26

3.08

1.2

1.4

—

(3012501) Base excess in Blood by calculation

3.51

2.88

7.5

3.0

3.17

2.66

mmol/l

0.27

(3019800) Troponin T.cardiac [Mass/volume] in Serum or Plasma

585

0.55

2.62

2.5

4.4

156.70

41.57

ng/l

0.54

446

(43055089) Myosin Ab [Presence] in Serum or Plasma by Immunoblot

5.63

2.57

1.0

—

(42528593) TIF1-gamma Ab [Presence] in Serum by Line blot

7.34

2.57

1.0

—

(42529598) SUMO-activating enzyme subunit 1 Ab [Presence] in Serum by Line blot

7.34

2.57

1.0

—

(3013637) Mi-2 Ab [Presence] in Serum

7.34

2.57

1.0

—

(42529582) MDA5 Ab [Presence] in Serum by Line blot

7.34

2.57

1.0

—

(3001784) Prostate Specific Ag Free/Prostate specific Ag.total in Serum or Plasma

461

0.52

2.55

3.7

4.8

19.51

21.71

0.36

239

(3014051) Protein [Presence] in Urine by Test strip

366

0.48

2.50

2.5

3.5

—

0.00

—

(3011397) Hemoglobin [Presence] in Urine by Test strip

328

0.46

2.45

2.8

3.8

—

0.00

—

(3041096) Erythrocytes [Presence] in Urine by Automated

407

0.51

2.37

2.7

3.7

0.00

0.01

estimate

—

132

(3020460) C reactive protein [Mass/volume] in Serum or Plasma

110

1245

0.57

2.28

14.2

18.9

31.41

24.56

mg/l

0.99

1056

(706163) SARS-CoV-2 (COVID-19) RNA [Presence] in Respiratory system specimen by NAA with probe detection

712

0.61

2.22

3.2

2.8

—

(3022145) Colonoscopy Study observation

157

0.36

2.04

1.3

—

(3036086) Jo-1 extractable nuclear Ab [Units/volume] in Serum by Immunoassay

2.67

1.98

1.2

1.3

—

(3014791) Apolipoprotein B [Mass/volume] in Serum or Plasma

0.00

1.74

0.0

1.2

—

0.92

—

(3013742) Prealbumin [Mass/volume] in Serum or Plasma

136

1.82

1.71

2.7

2.6

0.24

0.21

g/l

1.81

126

(3000991) Gas panel - Venous blood

121

1.85

1.69

3.8

8.8

—

(3002256) Pathology report gross observation

181

0.47

1.64

1.1

1.3

—

(4094501) Cardiovascular stress test using bicycle ergometer

0.00

1.55

0.0

1.1

—

(3011831) Apolipoprotein B/Apolipoprotein A-I [Percentile]

0.00

1.55

0.0

1.1

—

0.78

—

(3000570) Elastase.pancreatic [Mass/mass] in Stool

0.00

1.54

0.0

1.4

—

300.49

—

(3008364) Apolipoprotein A-I [Mass/volume] in Serum or Plasma

0.00

1.52

0.0

1.2

—

1.57

—

(3042936) Bacteria identified in Isolate by Culture

222

0.50

1.50

1.2

2.2

—

(3018095) Leukocytes [#/volume] in Urine

524

0.66

1.45

3.8

4.3

50.79

71.63

e6/l

0.25

382

(3029287) Urinalysis microscopic panel [#/volume] - Urine by Automated count

513

0.65

1.45

3.2

3.5

—

(3008152) Bicarbonate [Moles/volume] in Arterial blood

104

1.83

1.44

5.8

11.8

28.55

24.76

mmol/l

2.49

(3002385) Erythrocyte [DistWidth] in Red Blood Cells

1031

0.69

1.42

19.4

23.1

13.60

13.77

0.99

1023

(3016771) Amylase [Enzymatic activity/volume] in Serum or Plasma

457

0.64

1.41

1.5

3.0

52.63

63.22

u/l

0.51

430

(3036481) Cortisol [Moles/volume] in Serum or Plasma

146

0.45

1.41

1.1

2.3

420.43

373.96

nmol/l

—

132

(3048689) Calprotectin [Mass/mass] in Stool

149

0.44

1.41

3.7

2.0

301.57

134.16

ug/g

—

128

(3039443) Prostate specific Ag panel - Serum or Plasma

0.00

1.36

0.0

1.6

—

(3015399) Transferrin receptor.soluble [Mass/volume] in Serum or Plasma

352

0.62

1.32

1.1

2.1

2.09

3.01

mg/l

1.15

307

(3002109) Cholesterol in LDL/Cholesterol in HDL [Mass Ratio] in Serum or Plasma

117

0.41

1.31

1.8

2.4

3.10

3.53

ratio

—

106

(3034780) Angiotensin converting enzyme [Enzymatic activity/volume] in Serum or Plasma

1.98

1.27

1.2

2.2

36.17

43.66

u/l

0.86

(4035726) Immunohistochemistry procedure

126

0.45

1.23

1.3

—

(3009214) Lutropin [Units/volume] in Serum or Plasma

0.00

1.17

0.0

1.1

—

6.19

—

(3005702) Mycobacterium sp identified in Specimen by Organism specific culture

0.00

1.17

0.0

1.3

—

(3051387) C reactive protein [Mass/volume] in Capillary blood

0.00

1.17

0.0

4.7

—

24.69

—

(3006418) Campylobacter sp identified in Tissue by Organism specific culture

0.00

1.15

0.0

1.2

—

(42529406) Shigella sp [Presence] in Stool by Culture

0.00

1.15

0.0

1.2

—

(3014765) Yersinia sp identified in Stool by Organism specific culture

0.00

1.15

0.0

1.2

—

(3048929) Epstein Barr virus Ab [Presence] in Serum

0.00

1.15

0.0

1.2

—

(3027945) Reticulocytes/Erythrocytes in Blood

191

0.54

1.14

4.4

3.4

2.38

1.74

1.45

171

(43054914) Glucose tolerance 2 hours panel - Serum or Plasma

124

0.46

1.11

1.8

1.3

—

(3001079) Blood group antibody screen [Presence] in Serum or Plasma

613

0.72

1.05

2.1

3.1

—

estimate

—

(3002582) Erythrocytes [#/volume] in Urine

476

0.71

1.04

3.4

3.6

125.13

172.13

e6/l

0.10

365

(40758558) Short blood count panel - Blood

430

0.70

0.99

4.0

6.9

—

(3011371) Neisseria gonorrhoeae DNA [Presence] in Specimen by NAA with probe detection

0.00

0.99

0.0

2.1

—

(40768793) Breast Pathology biopsy report

0.00

0.97

0.0

1.3

—

(3000067) Parathyrin.intact [Mass/volume] in Serum or Plasma

103

0.47

0.93

1.4

3.8

66.40

74.60

ng/l

—

(40763571) Iron/Transferrin [Ratio] in Serum or Plasma

211

0.63

0.86

1.4

2.7

23.79

22.63

0.12

197

(46235355) HIV 1 and 2 tests - Meaningful Use set

183

1.44

0.83

1.2

1.7

—

(3012544) pH of Venous blood

140

1.49

0.82

1.5

4.0

7.37

7.38

—

(3007080) Epstein Barr virus nuclear IgG Ab [Units/volume] in Serum

0.00

0.80

0.0

1.1

—

377.30

—

(3013327) Hepatitis A virus IgM Ab [Presence] in Serum

0.00

0.80

0.0

1.0

—

(3004383) Neutrophil cytoplasmic Ab.classic [Titer] in Serum by Immunofluorescence

0.00

0.79

0.0

1.1

—

(3007844) Epstein Barr virus capsid IgM Ab [Units/volume] in Serum by Immunoassay

0.00

0.79

0.0

1.2

—

(3016650) Hepatitis A virus Ab [Presence] in Serum

0.00

0.79

0.0

1.1

—

(40768797) Stomach Pathology biopsy report

194

0.64

0.77

1.0

1.3

—

(3037522) Nuclear Ab [Titer] in Serum

186

1.41

0.76

1.3

246.67

493.91

titre

—

(3019284) Hepatitis B virus surface Ag [Presence] in Serum

166

0.64

0.69

1.3

1.4

—

(21494755) Public health laboratory ask at order entry panel

0.51

0.69

1.2

1.5

—

(36031861) Influenza virus A and B and SARS-CoV-2 (COVID-19) and Respiratory syncytial virus RNA panel - Respiratory system specimen by NAA with probe detection

1.58

0.68

2.0

1.8

—

(3026008) Bacteria identified in Urine by Culture

396

0.76

0.68

3.5

—

(3007853) Bacteria identified in Skin by Aerobe culture

165

0.64

0.67

1.4

1.7

—

(3046524) Influenza virus A Ag [Presence] in Nasopharynx by Immunoassay

1.81

0.67

1.0

1.8

—

(3043362) Influenza virus B Ag [Presence] in Nasopharynx by Immunoassay

1.81

0.67

1.0

1.8

—

(3047181) Lactate [Moles/volume] in Blood

1.62

0.66

6.3

17.7

0.92

1.18

mmol/l

—

(3030467) Casts [#/volume] in Urine by Automated count

405

0.76

0.66

3.2

3.4

1.17

0.54

e6/l

0.62

297

(3012095) Magnesium [Moles/volume] in Serum or Plasma

274

1.31

0.64

1.5

3.6

0.84

0.82

mmol/l

0.44

258

(4010399) Spirometry for bronchospasm with prolonged evaluation after bronchodilator

113

1.47

0.64

1.2

1.4

—

(3038288) Influenza virus B RNA [Presence] in Specimen by NAA with probe detection

184

1.36

0.63

1.8

2.1

—

(3044640) Blood type and Crossmatch panel - Blood

434

0.78

0.62

2.0

2.6

—

(3000494) Fungus identified in Specimen by Culture

184

0.68

0.61

1.2

1.7

—

(3014576) Chloride [Moles/volume] in Serum or Plasma

203

1.34

0.61

3.9

7.1

102.81

104.14

mmol/l

0.69

203

(3005988) Vibrio sp identified in Specimen by Organism specific culture

0.00

0.61

0.0

1.6

—

(21493466) Plesiomonas shigelloides DNA [Presence] in Stool by NAA with non-probe detection

0.00

0.61

0.0

1.5

—

(3025468) Yersinia sp identified in Specimen by Organism specific culture

0.00

0.61

0.0

1.6

—

(3012568) Campylobacter sp identified in Specimen by Organism specific culture

0.00

0.61

0.0

1.5

—

(3024522) Salmonella sp identified in Specimen by Organism specific culture

0.00

0.61

0.0

1.6

—

(21494434) Karyotype in Bone marrow

0.00

0.61

0.0

1.1

—

(3008757) Leukocyte morphology finding [Identifier] in Blood

0.00

0.60

0.0

4.6

—

(3028369) Herpes simplex virus 1+2 DNA [Presence] in Specimen by NAA with probe detection

0.00

0.60

0.0

1.5

—

(1001926) Buprenorphine [Presence] in Urine by Screen method

0.00

0.60

0.0

1.3

—

(3016881) Enterovirus RNA [Presence] in Specimen by NAA with probe detection

0.00

0.60

0.0

2.1

—

(3015816) F5 gene p.Arg506Gln [Presence] in Blood or Tissue by Molecular genetics method

0.00

0.60

0.0

1.2

—

(3032080) INR in Blood by Coagulation assay

681

0.83

0.51

9.7

14.4

1.24

1.27

inr

0.15

567

(3003694) ABO and Rh group [Type] in Blood

339

0.79

0.50

1.2

1.4

—

(3044938) Influenza virus A RNA [Presence] in Specimen by NAA with probe detection

256

1.27

0.50

1.7

2.2

—

(3043924) Respiratory syncytial virus RNA [Identifier] in Specimen by NAA with probe detection

193

1.29

0.47

1.9

2.0

—

(3021337) Troponin I.cardiac [Mass/volume] in Serum or Plasma

260

0.78

0.45

3.1

4.1

144.95

259.15

ng/l

0.37

216

(3010521) Mycoplasma pneumoniae IgM Ab [Presence] in Serum by Immunoassay

1.58

0.42

1.2

1.1

—

3.44

—

(3037756) Immunofixation for Serum or Plasma

1.53

0.41

1.2

1.4

—

(3008401) Mugwort IgE Ab [Units/volume] in Serum

0.00

0.41

0.0

1.1

—

1.13

—

(3040363) Hepatitis A virus IgG Ab [Presence] in Serum by Immunoassay

0.00

0.41

0.0

1.0

—

(3014037) CD3+CD4+ (T4 helper) cells/cells in Blood

0.00

0.41

0.0

3.4

—

44.75

—

(3011288) Drugs identified in Urine by Screen method Nominal

0.00

0.41

0.0

1.3

—

(3003888) Timothy IgE Ab [Units/volume] in Serum

0.00

0.41

0.0

1.1

—

5.78

—

(3027529) Toxoplasma gondii IgM Ab [Units/volume] in Serum

0.00

0.41

0.0

1.3

—

(3043405) Microscopic observation [Identifier] in Specimen by Non-gynecological cytology method

0.00

0.41

0.0

1.2

—

(3023351) European house dust mite IgE Ab [Units/volume] in Serum

0.00

0.41

0.0

1.3

—

0.92

—

(3005570) Glucose [Moles/volume] in Urine

0.00

0.41

0.0

2.5

—

(3012447) Hantavirus puumala IgG Ab [Titer] in Serum

0.00

0.41

0.0

1.1

—

(3035933) Granulocytes/Leukocytes in Blood

1.49

0.40

2.6

2.5

53.20

59.36

—

(3000093) Morphology [Interpretation] in Blood Narrative

0.00

0.40

0.0

1.1

—

(3018559) Microscopic observation [Identifier] in Buccal smear by Cyto stain

0.00

0.40

0.0

1.2

—

(40768795) Lymph node Pathology biopsy report

0.00

0.39

0.0

1.1

—

(3025023) Rhinovirus RNA [Presence] in Specimen by NAA with probe detection

0.00

0.39

0.0

2.3

—

(4195642) Thrombophilia screening test

0.00

0.39

0.0

1.2

—

(3012202) Varicella zoster virus DNA [Presence] in Specimen by NAA with probe detection

0.00

0.39

0.0

1.4

—

(42868716) Shigella species+EIEC invasion plasmid antigen H ipaH gene [Presence] in Stool by NAA with probe detection

0.00

0.39

0.0

1.6

—

(43054903) Holo-transcobalamin II [Moles/volume] in Serum

587

0.85

0.39

1.9

2.2

88.10

96.02

pmol/l

0.78

296

(40761536) Microorganisms panel - Urine sediment

114

0.69

0.38

5.6

3.6

—

(3019225) pH of Specimen

122

0.72

0.37

2.3

4.2

7.36

7.34

—

(3016921) Smith extractable nuclear Ab [Units/volume] in Serum

1.45

0.36

1.0

1.3

—

3.18

—

(3006999) Ribonucleoprotein extractable nuclear Ab [Units/volume] in Serum

1.41

0.35

1.0

1.3

—

2.01

—

(3007164) IgA [Mass/volume] in Serum or Plasma

261

0.82

0.33

1.5

1.4

2.24

2.81

g/l

0.64

160

(4034850) Laboratory test

1.29

0.32

5.2

12.8

—

(3018006) Microscopic observation [Identifier] in Cervix by Cyto stain.thin prep

131

0.75

0.32

1.3

1.4

—

(3021347) Calcium.ionized [Moles/volume] in Serum or Plasma

639

0.87

0.31

4.2

7.4

1.21

mmol/l

0.03

592

(3021879) Hepatitis B virus core Ab [Presence] in Serum

107

0.73

0.30

1.4

—

(46236098) ABO and Rh group [Type] in Blood by Confirmatory method

309

0.85

0.29

2.0

2.7

—

(3017143) Hepatitis C virus Ab [Presence] in Serum

150

0.78

0.28

1.2

1.5

—

(3019832) Treponema pallidum Ab [Presence] in Serum

1.28

0.28

1.1

1.6

—

(3023368) Bacteria identified in Blood by Culture

422

0.87

0.28

4.3

5.3

—

(3016251) Hemoglobin.gastrointestinal [Presence] in Stool

0.68

0.26

1.4

2.3

—

(3033658) Prothrombin time (PT) actual/Normal

344

1.14

0.24

4.2

4.4

87.08

87.94

0.08

337

(3024891) Influenza virus A+B Ag [Presence] in Specimen

1.33

0.23

1.0

1.4

—

(3006315) Basophils [#/volume] in Blood

690

1.11

0.23

5.5

6.8

0.03

0.04

e9/l

2.06

603

(3051552) Clostridioides difficile toxin genes [Presence] in Stool by NAA with probe detection

104

0.76

0.22

1.4

1.6

—

(37020957) Sapovirus genogroups I+II+IV+V RNA [Presence] in Stool by NAA with probe detection

0.00

0.21

0.0

1.6

—

(42869457) Rotavirus RNA [Identifier] in Stool by NAA with probe detection

0.00

0.21

0.0

1.6

—

(3028308) Erythrocytes [#/volume] in Pleural fluid

0.00

0.21

0.0

1.5

—

71100.00

—

(3014133) Dog dander IgE Ab [Units/volume] in Serum

0.00

0.21

0.0

1.1

—

3.16

—

(3049539) Genetic diseases [Identifier] in Blood or Tissue by FISH Nominal

0.00

0.21

0.0

1.1

—

(3003191) Choriogonadotropin [Presence] in Serum or Plasma

0.00

0.21

0.0

1.2

—

(40765096) Chromosome analysis panel by Banding

0.00

0.21

0.0

1.1

—

(37020937) Giardia lamblia DNA [Presence] in Stool by NAA with probe detection

0.00

0.21

0.0

1.0

—

(3025018) Bordetella pertussis Ab [Titer] in Serum

0.00

0.21

0.0

1.2

—

(36305771) Cryptosporidium sp DNA [Presence] in Stool by NAA with probe detection

0.00

0.21

0.0

1.0

—

(40760543) Extractable nuclear Ab [Presence] in Serum by Immunoblot

0.00

0.21

0.0

1.2

—

(3049506) Microalbumin [Mass/time] in Urine collected for unspecified duration

0.00

0.21

0.0

2.0

—

(21494815) CD4 cells/Lymphocytes in Specimen

0.00

0.21

0.0

2.3

—

32.87

—

(43055361) Metamyelocytes/Leukocytes [Pure number fraction] in Blood by Manual count

0.00

0.21

0.0

4.8

—

0.92

—

(3017817) Protein [Mass] in Urine collected for unspecified duration

0.00

0.21

0.0

5.0

—

832.83

—

(40758895) Direct antiglobulin test.complement C3d specific reagent [Presence] on Red Blood Cells

0.00

0.21

0.0

2.1

—

(40758897) Direct antiglobulin test.IgG specific reagent [Presence] on Red Blood Cells

0.00

0.21

0.0

2.1

—

(40768441) Liver Pathology biopsy report

0.00

0.21

0.0

1.5

—

(3024889) Methemoglobin/Hemoglobin.total in Venous blood

1.27

0.21

1.7

2.7

0.67

0.62

—

(3028707) Methadone [Presence] in Urine by Screen method

0.00

0.21

0.0

1.1

—

(3045788) Cell count panel - Pleural fluid

0.00

0.21

0.0

1.4

—

(40763082) Lactate dehydrogenase [Enzymatic activity/volume] in Pleural fluid by Lactate to pyruvate reaction

0.00

0.21

0.0

1.3

—

351.21

—

(3012441) Differential panel - Pleural fluid

0.00

0.21

0.0

1.8

—

(3021125) Hepatitis C virus RNA [Presence] in Serum or Plasma by NAA with probe detection

0.00

0.21

0.0

1.5

—

(3026725) Estradiol (E2) [Moles/volume] in Serum or Plasma

0.00

0.21

0.0

1.4

—

0.15

—

(3001334) Neutrophil cytoplasmic Ab [Units/volume] in Serum

1.26

0.20

1.0

1.1

—

(40768806) Pleura Pathology biopsy report

0.00

0.20

0.0

1.9

—

(3009595) Pneumocystis jirovecii DNA [Presence] in Specimen by NAA with probe detection

0.00

0.20

0.0

1.9

—

(3010726) Horse dander IgE Ab [Units/volume] in Serum

0.00

0.20

0.0

1.1

—

0.36

—

(3018301) Testosterone Free [Moles/volume] in Serum or Plasma

0.00

0.20

0.0

1.4

—

171.56

—

(42529200) Cancer Ag 15-3 [Units/volume] in Serum or Plasma by Immunoassay

0.00

0.20

0.0

5.1

—

90.19

—

(3018677) aPTT in Platelet poor plasma by Coagulation assay

217

0.86

0.20

1.4

2.0

31.58

29.17

0.61

212

(4024509) Urine culture

1.20

0.18

1.7

1.9

—

(3001604) Monocytes [#/volume] in Blood

689

1.09

0.16

5.5

6.7

0.55

0.60

e9/l

1.06

602

(3013650) Neutrophils [#/volume] in Blood by Automated count

759

1.09

0.16

6.0

11.2

4.11

4.09

e9/l

0.02

670

(3003510) Neisseria gonorrhoeae DNA [Presence] in Urine by NAA with probe detection

0.78

0.16

1.0

1.8

—

(3024950) Chlamydia trachomatis DNA [Presence] in Urine by NAA with probe detection

0.76

0.16

1.2

2.0

—

(586526) SARS-CoV-2 (COVID-19) RNA [Presence] in Nasopharynx by NAA with probe detection

0.75

0.16

1.0

1.5

—

(3010517) Carboxyhemoglobin/Hemoglobin.total in Venous blood

1.22

0.16

1.7

2.7

0.76

1.23

—

(3033319) Streptococcus pyogenes Ag [Presence] in Throat

0.81

0.15

1.0

1.4

—

(3021589) Normoblasts [#/volume] in Blood

588

0.92

0.14

10.1

13.4

0.00

e9/l

0.77

486

(40760892) CBC W Ordered Manual Differential panel - Blood

307

1.10

0.13

4.6

6.0

—

(42870588) Differential panel, method unspecified - Blood

455

1.08

0.13

5.9

6.6

—

(3013115) Eosinophils [#/volume] in Blood

706

1.07

0.11

5.6

7.0

0.14

0.19

e9/l

2.79

629

(40762366) Oxygen capacity [Volume Fraction] in Arterial blood

1.16

0.09

8.6

14.9

17.43

15.37

—

(3030306) Epithelial cells.non-squamous [#/volume] in Urine by Automated count

247

0.92

0.09

2.7

3.1

0.76

1.08

e6/l

0.30

136

(3044254) Respiratory syncytial virus RNA [Presence] in Specimen by NAA with probe detection

1.04

0.09

1.2

1.8

—

(3019198) Lymphocytes [#/volume] in Blood

700

1.05

0.09

5.7

6.8

3.27

2.01

e9/l

0.35

628

(3023420) DNA double strand Ab [Units/volume] in Serum

1.06

0.08

1.6

1.5

—

7.71

—

(3022250) Lactate dehydrogenase [Enzymatic activity/volume] in Serum or Plasma by Lactate to pyruvate reaction

176

1.09

0.08

3.2

6.3

198.58

236.90

u/l

3.10

166

(3051714) Fibrin D-dimer FEU [Mass/volume] in Platelet poor plasma

315

0.94

0.07

1.8

1.7

1.51

1.73

mg/l

0.10

253

(3045783) Sodium and Potassium panel [Moles/volume] - Serum or Plasma

152

0.91

0.06

5.7

9.1

—

(3018418) pH of Serum or Plasma

435

0.95

0.06

2.1

4.6

7.40

0.36

313

(3016431) Calcium.ionized [Moles/volume] adjusted to pH 7.4 in Serum or Plasma

691

0.97

0.03

4.3

8.3

1.23

1.21

mmol/l

2.23

602

(3029879) Epithelial cells.squamous [#/volume] in Urine by Automated count

228

0.96

0.02

2.6

3.3

1.19

2.89

e6/l

—

117

(3019902) Methicillin resistant Staphylococcus aureus [Presence] in Specimen by Organism specific culture

154

1.04

0.00

5.4

3.8

—

(3009035) Cobalamin (Vitamin B12) [Moles/volume] in Serum or Plasma

288

1.01

0.00

1.3

1.9

442.92

461.64

pmol/l

0.23

242

(3042194) Human metapneumovirus RNA [Presence] in Specimen by NAA with probe detection

0.92

0.00

1.4

1.6

—

(3011960) Natriuretic peptide B [Mass/volume] in Serum or Plasma

0.93

0.00

2.1

2.7

263.78

233.45

ng/l

—

(37020445) Astrovirus RNA [Presence] in Stool by NAA with probe detection

0.00

-0.00

0.0

1.6

—

(3000855) Microscopic observation [Identifier] in Vaginal fluid by Gram stain

0.00

-0.00

0.0

2.4

—

(36660697) Celiac disease serology panel - Serum

0.90

-0.00

1.2

—

(3029536) Hepatitis C virus RNA [Units/volume] (viral load) in Specimen by NAA with probe detection

0.00

-0.00

0.0

1.3

—

(3030136) 5-Hydroxyindoleacetate [Moles/volume] in Serum or Plasma

0.00

-0.00

0.0

1.9

—

60.86

—

(4015189) Microbial culture of sputum

0.00

-0.00

0.0

4.2

—

(3035880) pH of Pleural fluid

0.00

-0.00

0.0

1.2

—

7.37

—

(3028679) Herpes simplex virus Ab [Presence] in Serum

0.00

-0.00

0.0

1.0

—

(3022689) Creatine [Moles/volume] in Urine

0.00

-0.00

0.0

1.6

—

10.22

—

(3021197) Magnesium Ionized [Moles/volume] in Serum or Plasma

0.00

-0.00

0.0

2.1

—

0.61

—

(1617658) Protocol used for examination of sentinel lymph nodes

0.00

-0.00

0.0

1.0

—

(3013727) Leukocytes other/Leukocytes in Blood

0.00

-0.00

0.0

6.5

—

37.83

—

(3019897) Erythrocyte [DistWidth] in Red Blood Cells by Automated count

0.00

-0.00

0.0

3.2

—

13.28

—

(3002079) Sodium [Moles/time] in 24 hour Urine

0.00

-0.00

0.0

1.2

—

131.94

—

(3021162) Amylase [Enzymatic activity/volume] in Specimen

0.00

-0.00

0.0

2.2

—

10944.80

—

(3000492) Spirometry study

120

1.00

-0.00

1.3

1.5

—

(3010375) cycloSPORINE [Mass/volume] in Blood

0.00

-0.00

0.0

38.2

—

115.60

—

(3026389) Candida sp identified in Specimen by Organism specific culture

0.00

-0.00

0.0

1.2

—

(3005156) Respiratory syncytial virus A RNA [Presence] in Specimen by NAA with probe detection

0.00

-0.00

0.0

2.7

—

(3013139) Helicobacter pylori Ag [Presence] in Stool

0.88

-0.00

1.2

1.3

—

(46235759) Influenza virus B RNA [Presence] in Nasopharynx by NAA with probe detection

0.98

-0.00

1.2

2.2

—

(3008536) Aspergillus sp Ab [Presence] in Serum

0.00

-0.00

0.0

1.7

—

(42529528) Centromere protein B Ab [Units/volume] in Serum by Line blot

0.00

-0.00

0.0

1.3

—

(3002148) Methylenedioxymethamphetamine [Presence] in Urine by Screen method

0.00

-0.00

0.0

1.0

—

(3029023) Hepatitis E virus IgG Ab [Presence] in Serum by Immunoassay

0.00

-0.00

0.0

1.0

—

(46235128) Lupus anticoagulant aPTT and dRVVT screening panel W Reflex

0.00

-0.00

0.0

1.0

—

(44816844) Macroprolactin [Units/volume] in Serum or Plasma

0.00

-0.00

0.0

1.8

—

213.67

—

(42529527) Centromere protein A Ab [Units/volume] in Serum by Line blot

0.00

-0.00

0.0

1.0

—

(3017704) Immunofixation for Urine

0.00

-0.00

0.0

1.6

—

(3053028) Streptococcus sp identified in Specimen by Organism specific culture

0.00

-0.00

0.0

1.0

—

(3035947) Staphylolysin Ab [Units/volume] in Serum

0.00

-0.00

0.0

1.2

—

(3022058) Hepatitis B virus DNA [Presence] in Serum or Plasma by NAA with probe detection

0.00

-0.00

0.0

1.4

—

(3003245) Complement C1 esterase inhibitor [Mass/volume] in Serum or Plasma

0.00

-0.00

0.0

1.4

—

0.31

—

(3007821) Glucose [Moles/volume] in Serum or Plasma --baseline

0.00

-0.00

0.0

1.0

—

6.37

—

(3006922) Hepatitis E virus Ab [Presence] in Serum

0.00

-0.00

0.0

1.0

—

(3000108) Respiratory syncytial virus B RNA [Presence] in Specimen by NAA with probe detection

0.00

-0.00

0.0

2.7

—

(3044007) Cell count panel - Peritoneal fluid

0.00

-0.00

0.0

1.2

—

(21493195) Respiratory pathogens DNA and RNA tested for in Respiratory system specimen by NAA with probe detection

0.00

-0.00

0.0

2.4

—

(3016436) Lactate dehydrogenase [Enzymatic activity/volume] in Serum or Plasma

0.00

-0.00

0.0

5.8

—

217.62

—

(3037534) Parathyrin related protein [Mass/volume] in Serum or Plasma

0.00

-0.00

0.0

1.5

—

66.94

—

(3035457) Cefaclor IgE Ab [Units/volume] in Serum

0.00

-0.00

0.0

1.0

—

0.02

—

(3032567) Hepatitis B virus DNA [Units/volume] (viral load) in Serum or Plasma by NAA with probe detection

0.00

-0.00

0.0

1.0

—

(3013566) Clostridioides difficile [Presence] in Stool by Organism specific culture

0.00

-0.00

0.0

1.0

—

(46237023) Hepatitis B virus core and surface Ab and surface Ag panel - Serum

1.00

-0.00

1.6

1.1

—

(36306090) Helicobacter pylori [Presence] in Tissue by Organism specific culture

0.00

-0.00

0.0

1.1

—

(3002619) Bacteria identified in Specimen by Culture

0.00

-0.00

0.0

1.1

—

(3050898) Methicillin resistant Staphylococcus aureus [Presence] in Genital specimen by Organism specific culture

0.00

-0.00

0.0

1.8

—

(3044936) Clostridioides difficile toxin A+B [Presence] in Stool by Immunoassay

0.00

-0.00

0.0

1.0

—

(3002222) Hepatitis E virus IgM Ab [Presence] in Serum

0.00

-0.00

0.0

1.0

—

(3033799) Differential panel - Peritoneal fluid

0.00

-0.00

0.0

1.2

—

(40758292) HTLV I+II Ab panel - Serum

0.00

-0.00

0.0

1.6

—

(4211845) Urine protein measurement

0.00

-0.00

0.0

2.0

—

(3037692) Legionella sp identified in Specimen by Organism specific culture

0.00

-0.00

0.0

1.3

—

(3023511) Choriogonadotropin [Units/volume] in Urine

0.00

-0.00

0.0

1.0

—

(3020491) Glucose [Moles/volume] in Blood

0.00

-0.00

0.0

2.8

—

6.34

—

(44816752) ERBB2 gene copy number/nucleus in Tissue by FISH

0.00

-0.00

0.0

1.1

—

(42868414) European tick borne encephalitis virus IgM Ab [Presence] in Serum by Immunoassay

0.00

-0.00

0.0

1.4

—

(3049714) Procollagen type I.N-terminal propeptide [Mass/volume] in Serum

0.00

-0.00

0.0

1.0

—

99.20

—

(3008832) Norclozapine [Moles/volume] in Serum or Plasma

0.00

-0.00

0.0

7.2

—

1021.50

—

(40766800) Mycobacterium tuberculosis stimulated gamma interferon release by CD4+ T-cells [Units/volume] corrected for background in Blood

0.00

-0.00

0.0

1.2

—

Mortality – FinRegistry

↥

This endpoint is excluded from FinRegistry analyses (omitted endpoint).

Relationships between endpoints

↥

Index endpoint: MNMED_RILUZOLE – Use of riluzole

GWS hits: -

This endpoint is excluded from FinRegistry analyses (omitted endpoint).

≡ Risteys

R14

FinnGen R13 + FinRegistry

FinnGen R12 + FinRegistry

FinnGen R11 + FinRegistry

FinnGen R10 + FinRegistry

FinnGen R10

FinnGen R9

FinnGen R8

FinnGen R7

FinnGen R6

FinnGen R5

FinnGen R4

FinnGen R3

Use of riluzole

Endpoint definition

Endpoint definition steps

FinnGen

Phenotype data

1. Apply sex-specific rule

2. Check conditions

3. Check pre-conditions, main-only, mode, registry filters

4. Check minimum number of events

5. Include endpoints

6. Filter based on genotype QC (FinnGen only)

All original rules

Similar endpoints

Case counts by codes

Case counts by code for Use of riluzole (MNMED_RILUZOLE)

Summary Statistics

-FinRegistry-

-FinnGen-

Key figures

-FinnGen-

Age distribution of first events

-FinnGen-

Year distribution of first events

-FinnGen-

Cumulative Incidence Function

CodeWAS

Matched cohort

TimeCodeWAS

LabWAS

Mortality – FinRegistry

Relationships between endpoints